IQST Runs a Diversified Business with Divisions Focused on Telecommunications, Fintech, Electric Vehicles, Artificial Intelligence and More
They are well on track to their $340 Million Revenue Forecast for 2025 after Exploding from $13.8 million in 2018 to $283 million in 2024
IQST ran the Gamut From Pink Sheets to QB, then OTCQX, and now NASDAQ Just Days Ago! —without a capital raise or any shareholder dilution
Company Just Sparked Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan
Hello Everyone,
What a wild May it has been. It really has been an incredible month with some HUGE triple digit runners. We saw way more than we usually do. I do not know what that is an indicator of but I will take it.
We have one last company for you to look at and the story on this one is absolutely incredible. The growth alone is jaw dropping as the company claims to be on track to 1 Billion in Revenues by 2027. It just uplisted to the Nasdaq without any rain or dilution. When I say just uplisted I mean DAYS ago. IQST has only 11 sessions under its belt on the Nasdaq. The CEO says the company is coming to the Nasdaq with 20,000 shareholders.
The float has to be tiny. The company just completed a 1 for 80 reverse earlier this month, drastically reducing the outstanding. Since the first session IQST has drifted lower on light interest after a big first session of trading. While this one is higher priced than we usually look at, the prospects for movement are the same if not more given the catalysts involved right now.
This is a company that is not to be overlooked at these levels. IQST is a multinational technology company offering cutting-edge solutions in Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Telecom, High-Tech Telecom Services (eSIM, roaming, cloud), with over 600 global business relationships.They deliver high-value, high-margin services to its extensive global customer base.
In 2024, IQSTEL reported $283 million in revenue, yet their market cap remained at only about 10% of that figure. They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST.
MAIN CUSTOMERS
IQST – IQSTEL Sparks Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan
NEW YORK, May 29, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a rapidly expanding multinational leader in telecommunications and emerging technologies, proudly announces the execution of a definitive agreement to acquire 51% of GlobeTopper — a dynamic fintech innovator with operations across America, Europe, and Africa. The transaction becomes effective July 1, 2025, marking a transformative milestone in IQSTEL’s journey toward becoming a $1 billion revenue corporation.
This milestone follows the signing of a Memorandum of Understanding (MOU) on March 21, 2025, and reinforces IQSTEL’s strategic vision to scale its high-tech fintech footprint globally.
GlobeTopper’s Vision and Forecasts
GlobeTopper’s strong market positioning is evident in its current standalone performance — planning to generate over $65 million in profitable revenue in 2025 alone. Its financial outlook for the next three years reflects steady growth and operational momentum.
Strategic Vision: A Masterpiece Commercial Move
IQSTEL’s decision to acquire GlobeTopper is rooted in a bold and deliberate strategic vision.
“We didn’t just acquire a company—we partnered with a growth engine,” said Leandro Iglesias, CEO of IQSTEL.
“Our goal is to take GlobeTopper’s innovative fintech products and services and scale them globally through IQSTEL’s powerful commercial platform — which already reaches over 600 of the largest telecom operators around the world.”
In parallel, GlobeTopper’s existing client base — including prominent multinational brands — opens the door for IQSTEL to expand its reach into new sectors, allowing deeper penetration into the enterprise and global brand markets.
“We believe the potential for growth is massive,” Iglesias continued. “This isn’t just an acquisition — it’s a masterpiece commercial move that brings together two agile organizations and sets the stage for something extraordinary.”
Together, IQSTEL and GlobeTopper will lead the next wave of convergence between fintech and telecommunications in high-value markets across Africa, Europe, and the Americas.
Strategic Synergy and Ongoing Leadership
As part of the transaction, Craig Span will continue in his role as CEO of GlobeTopper, ensuring leadership continuity and seamless integration into IQSTEL’s Fintech Division.
“This partnership with IQSTEL marks a new era for GlobeTopper,” said Craig Span, CEO of GlobeTopper.
“We’re incredibly excited to join forces with a Nasdaq-listed company that shares our vision, values, and ambition. With IQSTEL’s support, we’re ready to fast-track our growth and become a major player in the global fintech space.”
GlobeTopper will collaborate with GlobalMoneyOne.com, co-developing a 3-year business plan to position itself as a top-tier player in the global fintech ecosystem.
Accelerating Toward $1 Billion
“We’ve helped subsidiaries scale before, and we’re doing it again with GlobeTopper,” said Iglesias.
“This deal puts us firmly on track to reach a $400 million revenue run rate and achieve our targeted 80% telecom / 20% tech revenue mix by the end of this year.”
This acquisition strengthens IQSTEL’s position as a high-margin, tech-focused growth platform, advancing its $1 billion revenue goal by 2027.
Transaction Highlights
The transaction is valued at up to $700,000, structured to align performance with shareholder value:
$200,000 in staged cash payments
$500,000 in restricted IQSTEL common stock, issued at a 20% discount to the 5-day VWAP prior to closing
Performance-based Earn-Outs:
50% of EBITDA growth in Year 1 (paid in IQSTEL shares)
50% of EBITDA growth in Year 2 (paid in IQSTEL shares)
Earn-out shares priced at a 20% discount to the higher of the 5-day VWAP.
Additionally, IQSTEL plans to invest up to $1.2 million over the next 2 years to accelerate GlobeTopper’s growth and product roadmap. This investment is contingent upon GlobeTopper meeting specific quarterly financial targets, ensuring performance-driven alignment throughout the integration.
What’s Next
With GlobeTopper now part of the IQSTEL family, the company is moving faster and stronger toward its vision. IQSTEL remains laser-focused on scaling high-tech divisions, expanding its global footprint, and maximizing shareholder value.
“We’re building something big” added Iglesias — and the entire IQSTEL ecosystem is gaining powerful momentum”
About GlobeTopper
GlobeTopper is a leader Fintech company specializing in advanced B2B Top-Up solutions, enabling seamless cross-border financial transactions to something more along the lines of ‘global Fintech company specializing in the provision of B2B digital prepaid products with a unique focus on gift card programs and services. With a solid track record and a scalable, profitable business model, GlobeTopper is poised for exponential growth under IQSTEL’s leadership.
The details of this acquisition will be disclosed in an upcoming Form 8-K filing.
— IQSTEL Inc. (NASDAQ: IQST) (@IQstel) May 23, 2025
IQSTEL (NASDAQ: IQST) Issues Follow-Up Shareholder Letter Highlighting NASDAQ Benefits, $57.6M Q1 Revenue, and $14.58 Assets Per Share on Path to $1 Billion
NEW YORK, May 20, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a U.S.-based multinational technology company, today issued a follow-up shareholder letter to reinforce the strategic value of its recent NASDAQ uplisting and to highlight the company’s most important operational and financial metrics.
This communication outlines IQSTEL’s transformation into a high-tech global enterprise, backed by strong fundamentals and a clear path to $1 billion in annual revenue by 2027.
Key metrics and updates underscore why we believe our stock remains significantly undervalued:
Current Assets Per Share (Q1 2025): $14.58
Current Revenue Per Share: Over $100
Current Stockholders’ Equity Per Share (Q1 2025): $4.38
Trading212.com now supports IQST again for European-based investors
IQSTEL’s NASDAQ listing enhances visibility, unlocks institutional investment, increases customer confidence, and positions the company to execute larger, EBITDA-positive acquisitions without dilution.
Shareholder Letter – May 20, 2025
Dear Shareholders,
Just days ago, we celebrated our official listing on the NASDAQ Capital Market under the ticker IQST—a transformational milestone that opens the door to unprecedented commercial, financial, and strategic opportunities.
Following this milestone, we received several thoughtful questions from our shareholders regarding the impact of this listing and our forward strategy. In response, we’ve prepared this Shareholder Letter to provide greater clarity and reaffirm the benefits of this moment, while summarizing the most critical indicators of IQSTEL’s financial strength and long-term growth potential.
Key Shareholder Takeaways
Current Assets Per Share (Q1 2025): $14.58
Current Revenue Per Share: Over $100
Current Stockholders’ Equity Per Share (Q1 2025): $4.38
Business Relationships: 600+ global interconnections
Telecom Division (99% revenue stream): Positive Adjusted EBITDA and Positive Net Income
Trading212.com now supports IQST again for European-based investors
What Shareholders Can Expect as a NASDAQ Company
1. Institutional Access & Global Liquidity
IQSTEL is now available to institutional funds and platforms like Trading212.com in the UK and Europe.
Global retail and institutional investors can participate more easily in our story.
2. Commercial Trust and Growth Acceleration
We already handle hundreds of millions in B2B telecom transactions annually.
Our NASDAQ status boosts credibility with customers and partners—catalyzing growth.
3. Shareholder-Friendly Capital Structure
Fewer than 2.9 million shares outstanding.
No capital raise or dilution for the NASDAQ uplisting.
All convertibles mature in Q1 2026—no short-term pressure.
4. Revaluation Opportunity
IQSTEL trades at ~0.10x 2024 revenue.
NASDAQ peers in telecom/tech often trade at 1.0x or more—even without profitability.
5. Strong M&A Capability
Our stock is now a more attractive currency for acquiring EBITDA-positive businesses.
We are actively targeting strategic acquisitions in telecom, fintech, AI, and cybersecurity.
Delivering on Our Promises—Built on Execution, Not Hype
At IQSTEL, we don’t just set goals—we deliver on them. Over the past seven years, we’ve earned a reputation for consistent execution, operational discipline, and transparency. Everything we’ve told our nearly 20,000 shareholders we would accomplish—we have. That track record speaks louder than any forecast and forms the foundation for the next phase of our growth.
Here’s a summary of how we’ve kept our word:
Sustained Revenue Growth: From $13.8 million in 2018 to $283 million in 2024—consistently meeting or exceeding our revenue forecasts year after year.
Robust Corporate Governance: Audit, Compensation, and Ethics Committees are fully established, supported by an independent Board of Directors and annual shareholder meetings that ensure transparency and accountability.
NASDAQ Uplisting Achieved: From Pink Sheets to QB, then OTCQX, and now NASDAQ in 2025—without a capital raise or any shareholder dilution.
Enhanced Shareholder Value: Revenue Per Share now exceeds $100, a strong reflection of our disciplined approach to growth and value creation.
Balance Sheet Strength: We met NASDAQ’s equity requirements without raising capital—an uncommon achievement that shows the strength of our business.
Equity Growth: From a negative equity position of ($1.6 million) or -$0.11 per share in 2018, to $11.6 million or $4.38 per share as of March 31, 2025.
These are not projections. These are results. They represent our commitment to building a company that delivers real shareholder value—not just vision, but verifiable performance.
Because We Deliver on Our Promises, These Are the Goals We Are Now Pursuing in 2025
Our consistent execution over the past seven years gives us the confidence—and credibility—to set ambitious but achievable objectives for 2025. These goals are not aspirational statements; they are measurable targets rooted in our proven ability to grow revenue, manage costs, and build shareholder value. With a scalable model, a trusted global platform, and momentum from our NASDAQ listing, we believe the following objectives are well within reach:
Strategic Acquisitions: Targeting companies with positive EBITDA and synergy potential
Built for the Future
IQSTEL’s future is tech-driven and margin-focused. We’re now leveraging our trusted telecom platform to deliver:
High Tech Telecom Services: eSIM, roaming, numbering
Fintech Services: remittance, mobile banking
AI-Driven Customer Platforms: automation, support, lead generation
Cybersecurity Solutions: tailored for telecom operators and infrastructure clients
Final Thoughts
IQSTEL is now a global public company with robust fundamentals, scalable operations, and powerful visibility. With strong momentum and aligned shareholder interests, we are executing our plan to reach $1 billion in revenue by 2027—profitably and sustainably.
Thank you to our nearly 20,000 shareholders. The best is just beginning.
If you have any questions about our NASDAQ uplisting or our 2025 goals, please don’t hesitate to contact us at questions@iqstel.com.
Sincerely,
Leandro IglesiasPresident & CEOIQSTEL Inc. (NASDAQ: IQST)
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THREE THOUSAND USD AND ANTICIPATES TO RECEIVE MORE BY CORPORATE ADS LLC FOR A ONE DAY IQST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Wow……. What an incredible profile we just dished out to you. This thing ROCKETED almost 200% on massive interest. Everyone was talking about this one! Congrats if you caught a piece of that one!
Speaking of parabolic companies, unless you have been down in Antarctica looking for polar bears then you are going to remember FMST from the 1st of May when we brought it to you before it just went on a 300%+ run in under a month’s time.
Yes you read that right……300%. In fact, it made new highs of 4.34 TODAY!
Less than a month ago we brought this one to you at .96. .96 to 4.34 in a month. You don’t need to break the calculator out on that one.
We need to put FMST back on the menu and not because of the parabolic move that it just made over the past month. While that is important and cannot be overlooked, that is secondary as to why you need to research FMST again. Just days ago President Trump came in and changed the whole Uranium landscape.
President Trump just signed four explosive executive orders that will:
• Mandate 400 GW of U.S. nuclear capacity by 2050 (4X current levels), requiring 64,000+ tons of annual uranium—or 2.5X the amount of uranium at today’s current levels.
• Ban reliance on foreign uranium, notably Russian uranium imports by 2028
• Fast-track reactor approvals (18 months for new builds) and prioritize Small Modular Reactors (SMRs).
• Invoke the Defense Production Act to revive domestic uranium mining and enrichment.
This isn’t just policy—it’s a uranium demand shock
President Trump has just signed an executive order to overhaul the nuclear regulatory commission and this sent nuclear stocks surging in the past few days. FMST is making serious moves right now and is up more than 300% in the past month, but somehow this is still flying under the radar. They have a great location (Athabasca Basin), and a growing sector (nuclear).
And with a solid multi-billion-dollar partner, Denison Mines Corp backing them, this isn’t just a partner —they’re also Foremost’s largest shareholder. Denison CEO sits on Foremost’s board, offering direct access to Denison’s ISR mining expertise, future milling infrastructure, and streamlined permitting strategies. Denison just doesn’t back any company and offers credibility; it is like it is already partially derisked.
With Denison preparing to launch Canada’s first ISR uranium mine by 2028 , Foremost is perfectly aligned to benefit from that first-mover advantage.
As the demand for carbon free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy.
America currently produces just 200,000 pounds of uranium annually but requires 40 million pounds – a gap that is astounding, prioritized byTrump’s Executive Order to fast-track domestic and allied uranium development. While others scramble, Foremost Clean Energy (NASDAQ: FMST) is already securing resources in Canada—a stable, democratic jurisdiction the U.S. can turn to, to evade geopolitical tensions and any global shortages that may occur, and possible price spikes.
With its low-cost, high-grade assets in the Athabasca Basin, Foremost is uniquely positioned. They could be the next uranium company to address the coming market demands while insulating American utilities from potential price spikes and supply disruptions.
Foremost also has a portfolio of lithium projects which are located across 55,000 acres in Manitoba and Quebec. Now before I look at the investor’s presentation, it’s important to put some context on what’s going on in the nuclear energy sector right now.
Uranium prices have been rising for more than 5 years, peaking at over $100 in January 2024, but recently hit an 18-month low. Now, uranium is on the rise again. President Trump declared nuclear energy a national security priority and last week signed four new blockbuster executive orders to overhaul the nuclear sector. And this is a game changer for uranium explorers like Foremost. These include, reinvigorating the nuclear industrial base, ordering the reform of the nuclear energy commission, reforming nuclear reactor testing at the Department of Energy, and deploying advanced nuclear reactor technologies for national security.
This isn’t just a small policy change. It’s unleashing a uranium demand tsunami. And with the US relying on Canada for approximately 25% of its uranium, we should only expect that number to skyrocket from here. Meaning that foremost clean energy’s Athabasca basin projects just became strategic gold mines.
But FMST isn’t exploring just anywhere. This is the Athabasca basin. This could be the most elite uranium rich property on the planet. This is the only place on earth where uranium grades routinely come in at 10 to 100 times higher than the global average.
Their 10-property portfolio sits in the same proven geological corridor as Cameco’s McArthur River—one of the richest uranium mines ever discovered.
Foremost is going big in 2025. Their $6.5 million exploration program is the largest among Athabasca uranium juniors.
And the early results are already turning heads.
FMST’s very first drill program at its Hatchet Lake property revealed multiple mineralized intervals, 0.22% eU3O8 over 0.9 metres, within a 15-metre-wide zone of alteration. What does that actually mean?
• 0.22% uranium concentration is actually quite impressive for a first find—many operating uranium mines run at grades between 0.1-0.4%
• That 0.9-meter thickness is substantial enough to be economically interesting
• The 15-meter “alteration zone” surrounding it is basically a neon sign saying “there might be more uranium nearby
This is the same mining method Denison is pioneering just next door at Wheeler River. Though FMST may be holding future feed stock for Canada’s first ISR uranium mine. FMST is miles ahead of the other junior explorers.
While others are still hunting for targets, FMST is already intercepting mineralization at economic grades. They are in the exact right place at the exact right time. Looking at the recent investors presentation, FMST is rapidly growing.
Their projects consist of 10 prospective uranium properties strategically located within the world-renowned Athabasca Basin totaling over 330,000 acres.
Fig 1. Map of Foremost’s Uranium Properties With Nearby Mills, Mines and Deposits
And Denison Mines had done years of prior exploration on this portfolio, including drilling and geophysical surveys. Foremost was not starting from scratch like other juniors.
With Denison Mine’s extensive historical work already done, Foremost Clean Energy (NASDAQ: FMST) was provided a clear roadmap to high-priority targets —giving it an edge most early-stage explorers simply didn’t have.
Some of Foremost’s properties can be found alongside or within major uranium trends including the LaRocque corridor – host to IsoEnergy’s world-class Hurricane Deposit (48.6M lbs at 34.5% U3O8) , underscoring the high-grade discovery potential of Foremost’s projects.
With President Trump’s new executive orders, the company is positioned to help enable the uranium market renaissance with over 20 nations pledging to triple nuclear capacity by 2050. This is a projected period of sustained structural uranium supply shortages. There is also secondary lithium upside for this company with five Canadian lithium projects spanning 55,000 acres with long-term development potential.
The collaboration with Denison Mines is significant.
FMST’s deal with Denison makes it one of the rarest of rare junior explorers.
Denison Mines is a uranium developer and miner with access to a mill that separates uranium from ore. This suggests that if Foremost discovers a uranium deposit, they already have a partner capable of refining and delivering it to the market. The uranium market outlook is bullish and the small modular reactor market is expected to expand to over 8 billion by 2028. These SMRs are considered to be the future of nuclear power and some of the world’s largest companies are switching to these in order to power their data centers.
Late last year, Google announced that it’s backing nuclear power to supply energy to its ever increasing energy hungry AI data centers.Microsoft is also planning to tap into these nuclear reactors to fuel growing AI demand. The demand for nuclear power is increasing and RBC capital markets have stated that one thing is for certain; More investment into uranium supply is required to keep pace with the growing demand. That’s why investors are starting to pay attention to FMST.
Foremost isn’t just another explorer. It’s a well-capitalized drill ready opportunity in a sector set to explode with a game-changing partnership with Denison Mines.
With Denison preparing to launch Canada’s first ISR uranium mine by 2028, FMST is perfectly aligned to benefit from that first mover advantage. Canada already supplies around 25% of US uranium needs. This relationship is so essential that even the Trump administration has limited its recent uranium tariff to just 10%. This isn’t just trade, it’s energy security.
FMST holds 45 claims across 330,000 acres surrounding some of the world’s largest and highest grade uranium operations like Cigar Lake and MacArthur River. Think about how important this can be. Unlike most junior explorers focused on single targets, FMST is diversified across 10 separate properties each with multiple drill ready zones. This dramatically increases the odds of a major discovery. It also enables Foremost to launch multiple exploration campaigns simultaneously, something that very few of its peers can do, putting Foremost at the forefront of a market set to explode.
This is not just a small market rally. This is a generational shift. And Trump’s executive orders just lit a fire under the uranium market. Trump’s orders will quadruple US capacity to 400 gigawatt by 2050, requiring 2.5 times more uranium than today’s entire global supply. The Defense Production Act now treats uranium as national security infrastructure, prioritizing contracts with allies like Canada that supply the US with so much uranium.
We’ve already seen that AI and tech giants like Microsoft and Google are going nuclear, but there is currently a supply crunch. We now have 22 nations such as Britain and France pledging to triple nuclear capacity by 2050. Unfortunately, uranium mines can take more than 10 years to permit. This means that Foremost is perfectly positioned in the right place at the right time to take advantage of this.
Foremost in partnership with Denison is drilling the Athabasca basin just as uranium’s supply crisis hits.
Many analysts are projecting prices to triple to over $150 by 2026. Denison Mines holds nearly 20% of Foremost. Their operational support, board presence, and technical expertise give Foremost Energy rare credibility for a micro cap explorer.
The world demand for nuclear power looks set to skyrocket, demanding more uranium than ever. Foremost Energy’s deal with Denison Mines looks like it could be a gamechanger.
CATALYSTS
• Denison Partnership – There is no denying that what gives Foremost Clean Energy its strategic advantage: Denison Mines – By providing technical, operational, and financial support as well access to its vast industry networks that it took years to build, Foremost gains instant credibility and a multi-year head start over other peers. Denison owns almost ~20% of the outstanding shares and provides Foremost a competitive advantage offering confirmed targets and mineralized areas from years of previous exploration unlike other juniors starting from scratch.
• Tier-1 Uranium Portfolio with Near-Term Catalysts– It has 10 drill-ready properties (330,000 acres) in proven uranium corridors all near and surrounding mines, mills and infrastructure. It has its Hatchet Lake drill program where it announced a new uranium mineralization discovery. With a fully-funded$6.5Million 2025 exploration program and multiple drill programs on discovery-ready projects in the pipeline, any small catalyst could re-rate Foremost Clean Energy (NASDAQ:FMST) to levels never seen.
• Only 10.4 Million Outstanding Shares – This is like a tightly coiled spring with high insider ownership ~29.63. With such a tiny float, any major news or discovery could trigger explosive moves. Foremost is a potential powder keg for upside when uranium’s supply crunch meets its catalysts.
• Bonus Asset Exposure –Foremost also has “Lithium Lane” projects in Snow Lake, Manitoba, and the Lac Simard South project in Quebec, totaling over 55,000 acres offering exposure to battery metals at no extra cost to uranium-focused investors. This offers great added upside potential with zero added dilution,
• Nuclear Future – But wait, that deficit could grow to 91 million pounds of or so due to President Donald Trump’s executive order U.S. to expand its nuclear power resource by 4X by 2050. That could add as many as 58,000 more tons of uranium to the annual deficit. Companies like Foremost Clean Energy (NASDAQ:FMST) could be the solution to that crisis.
• Uranium Market Tailwinds – Trump’s landmark executive orders are expected to create a bullish outlook for uranium. Foremost is well-positioned to benefit situated in a stable jurisdiction aligning with U.S. national-security priorities. Tech giants like Microsoft and Amazon investing in nuclear power, surging AI and data center energy needs, and rapid SMR adoption. With new executive orders streamlining regulations and injecting billions in government funding, uranium demand and prices appear poised for parabolic growth.
Bottom Line: Foremost Clean Energy is a unique, catalyst-rich play on the uranium bull market, combining high-grade assets, strategic partnerships, and near-term drilling news flow. Investors could gain leveraged exposure to nuclear energy’s pivotal role in the clean energy transition—backed by a tight share structure and institutional support. At current levels, Foremost Clean Energy represents a high-conviction opportunity ahead of exploration results and broader uranium price appreciation.
Trump’s Executive Order transforms Foremost into a strategic national priority. With drilling results pending and uranium prices poised to surge, Foremost Clean Energy (NASDAQ: FMST, CSE: FAT) offers high leverage to the nuclear renaissance.
Fig 1. Map of Foremost’s Uranium Properties With Nearby Mills, Mines and Deposits
Collaboration with Denison
Denison (TSX: DML) (NYSE American: DNN) is a leading Athabasca Basin-focused uranium mining, development, and exploration company. Denison has a significant team of technical experts based in its office in Saskatoon, Saskatchewan, and this best-in-class team is ideal for supporting Foremost with its technical, operating and corporate initiatives. With the completion of Phase 1 of the Option Agreement, Denison became the largest shareholder of Foremost, holding ~19.95% of the shares outstanding and will retain an
Foremost is project operator during the term of the Option Agreement and will conduct the exploration programs with its geological team led by Dahrouge Geological Consulting, under the guidance of Jody Dahrouge. Mr. Dahrouge has a long history of uranium exploration and discovery, which includes the generation of several projects on behalf of Strathmore Minerals Corp. and its successors, including the J Zone (now the Tthe Heldeth Túé deposit) on the Waterbury Lake property, the JR Zone on the Patterson Lake North property and the Triple R Zone at the Patterson Lake South property. As a past President and COO of Fission Energy Corp. (“Fission Energy”), Jody played a key role in the acquisition and exploration of Fission Energy’s exploration property portfolio, which culminated with the eventual acquisition of Fission Energy by Denison in 2013.
Foremost Clean Energy Completes Highly Successful Exploration Drill Program at Hatchet Uranium Property and Provides Corporate Update
Highlights include:
Anomalous radioactivity was detected in 6 out of 10 completed drill holes, assay results are pending
At Tuning Fork, identification of an extensive hydrothermal system, strong alteration halo, and anomalous radioactivity surrounding drill hole TF-25-16
At Richardson, uranium mineralization was extended 50-metres along the Richardson conductor in drill hole RL-25-32 confirming system’s growth potential
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) completed a highly successful maiden winter drill program at the Hatchet Lake Uranium Property (“Hatchet“), which is located in the world-renowned Athabasca Basin region of northern Saskatchewan (Figure 1). The diamond drill program, originally planned as an 8-hole ~2,000 metre program, increased to 10-holes for over 2,400 metres following positive preliminary results from drill hole TF-25-16 – which discovered a new area of uranium mineralization highlighted by a mineralized interval of 0.10% eU3O8 over 6.5m, including 0.22% eU3O8 over 0.9m, within a 15m wide zone of alteration. Anomalous radioactivity was detected directly above and/or below the unconformity in six of the ten drill holes completed as part of the drill program: RL-25-32, TF-25-13, TF-25-16, TF-25-17, TF-25-18, and TF-25-19. Samples from the mineralized intersections in these drill holes have been submitted for assay and results are pending.
A notable highlight from the completion of the drill program was the 50 metre extension of previous mineralization along the Richardson conductor with drill hole RL-25-32, which returned two discrete mineralized intervals, as summarized in Table 1.
From (m)To (m)Length (m) (1)eU3O8 (%)(2)89.9490.140.20.082239.54239.740.20.077
(1) Final depth measurements and true thickness have not yet been determined(2) Composited at a 0.05% eU3O8 cut-off
Jason Barnard, Foremost’s President and CEO commented, “Our immediate success at Hatchet is attributable to Foremost’s unique collaboration with Denison Mines Corp. (“Denison”), where Denison’s extensive historic work on the property has identified several prospective structural settings for the potential discovery of uranium mineralization. We are particularly excited about the result from drill hole TF-25-16, which was the first hole completed in a 600-meter gap in an under-explored target area, resulting in the discovery of a new area of uranium mineralized. Based on follow up drilling in this area we are seeing strong radioactivity within graphitic shear zones, classic Athabasca-style clay alteration, and evidence of multiple mineralization events – making this an exciting new discovery with many of the hallmarks of a high-grade unconformity system that is open in every direction.”
“For our shareholders, these results validate our strategy and speak to the potential of Foremost’s ten uranium exploration properties under option from Denison: leveraging our strategic collaboration with Denison to make high-impact discoveries in one of the world’s premier uranium districts. As we await assays from Hatchet and plan further follow-up drilling, we’re equally excited to be able to apply the same exploration model across our portfolio, including expected upcoming drill programs at CLK and Murphy Lake South.”
Two drill holes were completed for initial follow up of the mineralization discovered in TF-25-16 – with TF-25-17 & TF-25-18 drilled off the same pad location as TF-25-16 and designed to examine the up-dip and down-dip extension of the mineralization intersected in TF-25-16. Two additional drill holes, TF-25-19 & TF-25-20, were completed to target the conductor axis 40-metres and 60-metres NE and SW, respectively, to test the along strike extension of the mineralization encountered in TF-25-16 (Figure 2). Extensive hydrothermal alteration (clay, hematite, and chlorite) was encountered with elevated radioactivity near the unconformity in each of the follow up drill holes, except for TF-25-20. These alteration markers are potentially indicative of a significant hydrothermal system, and when combined with confirmed uranium mineralization near major structural boundaries, represent one of the most reliable indicators of a high-potential area for follow-up.
The mineralization discovered in RL-25-32, at an approximate depth of 90 metres, is interpreted to be an extension of the mineralization intersected by RL-24-29 in 2024 (Figure 3). The second mineralized interval in RL-25-32, intersected mineralization at a depth of approximately 240 metres, which represents a new horizon for mineralization on the Richardson conductor, as previous drilling was generally aimed at shallow targets. Overall, the confirmation of mineralization along strike and the discovery of a new mineralized interval at depth is highly encouraging for the Richardson trend and suggests that there may be potential to discover additional mineralization along trend at depth, which is largely untested by historical drilling. Numerous additional target locations have been identified on the Richardson trend and warrant future drill testing.
Samples from drill core were collected during the drill program and shipped to SRC Geoanalytical Labs (“SRC”) and all applicable Portable Infrared Mineral Analyzer (“PIMA”) samples have been shipped to Rekasa Rocks Inc. to analyze and determine clay species. Assays are currently undergoing analysis and will be announced by news release upon completion, expected in the coming weeks.
Planned Follow-Up Exploration at Hatchet Lake
Work in 2025 will focus on integrating newly acquired geochemical, structural, and geological data to refine vectors toward the potential source of the recently discovered mineralization. Ground geophysics is currently being evaluated to help de-risk future drilling by delineating key structures and alteration zones identified in the latest campaign.
A winter 2025–2026 drill program is being planned to test newly defined anomalies and advance the geological understanding of the mineralization intersected in drillhole TF-25-16. Conducting the program during the winter season will enable drilling of high priority targets accessible by drilling from frozen lake surfaces. Additional follow-up exploration is scheduled across the broader Hatchet Lake property during this period, positioning the project for its next phase of discovery and development.
Technical Advisor Appointment
Foremost is pleased to report the appointment of Chad Sorba, Denison’s Vice President of Technical Services & Project Evaluation, as Technical Advisor to the Company pursuant to the transaction announced with Denison in 2024. Mr. Sorba is a Professional Geologist (P. Geo) with nearly two decades of experience in Canadian and international uranium exploration, evaluation, and development, and serves as Denison’s Qualified Person pursuant to NI 43-101. During his tenure at Denison, he has led various projects, including Denison’s flagship Wheeler River project, from discovery through to various levels of technical assessments, and evaluated numerous uranium projects for their economic potential, supporting several of Denison’s past asset acquisitions.
Mr. Sorba is a key technical leader of the Denison team that is pioneering the use of the In-Situ Recovery (“ISR”) mining method at certain high-grade uranium deposits in Saskatchewan, including involvement in the design and implementation of the first-of-its-kind ISR feasibility field test, which was successfully completed at Denison’s Phoenixdeposit. He was a critical member of the discovery team for both of Denison’s Phoenixand Gryphon uranium deposits and brings a wealth of Athabasca-focused expertise in uranium exploration to Foremost.
Mr. Sorba’s advisory role reinforces Foremost’s commitment to technical excellence, disciplined project development, and value-driven growth in the uranium sector. This collaboration aligns with the Company’s strategy to leverage world-class expertise as it progresses its exploration and development objectives.
Sampling, Analytical Methods and QA/QC Protocols
Following the completion of a drill hole, the hole is radiometrically logged using a downhole gamma probe, which collects readings of radioactivity every 0.1m along the length of the drill hole. Probe results are then calibrated using an algorithm calculated from the comparison of probe results against a geochemical reference. The gamma-log results provide an immediate radiometric equivalent uranium value (eU3O8%) for the hole, which, except in very high-grade zones, is reasonably accurate.
The downhole gamma probe data detailed in this news release was measured using a QL40-GR Natural Gamma probe from Mount Sopris that was calibrated on February 27, 2025, at the Grand Junction, CO, calibration test pits. Downhole measurements were taken at 0.10m intervals from the top of hole and depth corrected to the handheld RS-125 scintillometer, which was used to determine radioactivity of the core. Final depth measurements and true thickness have not yet been determined.
Where core has been recovered, sampling over mineralized interval is standardized 0.5m samples, except over intervals of strongly elevated radioactivity where select samples between 0.10 & 0.25m were collected. This includes shoulder samples 1m above and below the elevated zone. These select samples were split in half, with one kept in the core box and the other shipped to SRC for sample preparation and analysis. SRC is an independent laboratory with ISO/IEC 17025: 2005 accreditation for the relevant procedures. Control samples are implemented at a frequency of ~5%.
PIMA samples were taken systematically every 10m with increased sample density around strong alteration. Samples were dried and placed into Ziplock bags in preparation for shipping to Rekasa Rocks Inc. PIMA samples are used to identify the different clay species present in the sample to identify clay minerals that can assist in the identification of a potential hydrothermal source.
Qualified Person
The technical content of this news release has been reviewed and approved by Jordan Pearson, P. Geo., Project Geologist for Dahrouge Geological Consulting Ltd., and a Qualified Person under National Instrument 43-101, who has prepared and reviewed the content of this press release.
A qualified person has not performed sufficient work or data verification to validate the historical results in accordance with National Instrument 43-101. Although the historical results may not be reliable, the Company nevertheless believes that they provide an indication of the property’s potential and are relevant for any future exploration program.
CEO And President, And Non-Independent Executive Board Member
Jason Barnard
Mr. Barnard has over 31 years of capital markets experience. Since 2004, he has been self-employed as a private investor where he has been directly involved in raising over $500 million dollars for mining and exploration companies with a focused expertise on Canadian base metal companies.
Mr. Barnard started his career with McDermid St. Laurence Securities in 1991 as a stockbroker with primary focus in mining, and mining exploration companies. Mr. Barnard then worked at Canaccord Genuity from 1997 until 2004. Mr. Barnard holds a Bachelor of Arts degree with a major in Economics from Carlton University and has obtained The Canadian Securities Course license in 1990. He first started working with and financing Foremost Lithium, previously known as Far Resources, with founder, and President Keith Anderson in 2016 and is the Company’s largest shareholder.
David Cates
Independent Director
David Cates
Mr. Cates is a Chartered Professional Accountant (CPA, CA) and holds Master of Accounting (MAcc) and Honours Bachelor of Arts (BA) degrees from the University of Waterloo. Mr. Cates has extensive expertise in the Canadian and international uranium mining industry from over a decade of senior management and financial experience in various roles with Denison.
Mr. Cates was appointed President & CEO of Denison in 2015, having previously served as the company’s Vice President, Finance & Tax and Chief Financial Officer. Prior to joining Denison in 2008, Mr. Cates held positions at Kinross Gold Corp. and PwC LLP. Mr. Cates also serves as a Director of the Canadian Nuclear Association and of SkyHarbour Resources Ltd.
JODY DAHROUGE, B.SC., SP.C., – P. GEOL.
Geological Advisor
Jody Dahrouge
Mr. Dahrouge has been the President of Dahrouge Geological Consulting Ltd., a North American mineral exploration, consulting, and project management group, since 1988. He is a professional geologist with over 30 years’ experience and holds Bachelor of Science degrees in geology and computing science, both from the University of Alberta.
Mr. Dahrouge has been involved in all aspects of mineral exploration and development for a wide variety of commodities worldwide. Dahrouge Geological Consulting Ltd. has been instrumental in a multitude of grassroots discoveries across a wide variety of commodities and currently has boots on the ground on multiple Canadian and American projects
MARK FEDIKOW PH.D. P.GEO. CPG
Geoscientific Advisor
Mark Fedikow
Dr. Fedikow has over 40 years of experience as an exploration geochemist and a mineral deposits geologist working in both private and public sectors. He is a Fellow at the Association of Applied Geochemists, where he’s previously worked as a councilor. Dr. Fedikow has also served on numerous industry-related committees. He also pioneered the application of regional multimedia geochemical and mineralogical surveys in support of base and precious metal and diamond exploration in Manitoba.
During his 45-year career he has worked for a variety of junior and major mining exploration and mining companies and for the Manitoba Geological Survey as Chief Geologist of the Mineral Deposits Section. In 2001 he received the Provincial Geologists gold medal, a Canadian national award for excellence in the geosciences.
In 2002 Mark left the Manitoba Geological Survey to start his own company (Mount Morgan Resources Ltd.) providing consulting services to the metal and hydrocarbon exploration industry. He is currently registered as P.Eng. and P.Geo. with Engineers Geoscientists Manitoba (“EGM”), P.Geo. with the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists (NAPEG) and as a Certified Professional Geologist (C.P.G.) with the American Institute of Professional Geologists (“A.I.P.G.”), Westminster, Colorado, U.S.A.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY FMST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
The Company has assembled a world class team and is led by a CEO who has achieved more than $1B market caps on not one, but two previous companies!
In February of 2025, Aspire Biopharma, Inc. and PowerUp Acquisition Corp. successfully merged in a business combination to drive breakthrough innovations in FDA-approved drugs, nutraceuticals, and supplements
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
May has been an incredible month so far. We are going to talk a little more about that tomorrow but right now we want to focus on a brand new profile that we have never brought to your attention before.
This one has stabilized recently and is sitting at a price point right now that we feel could bring some attention to this one as we watch for a possible re-tracememt.
You will want to have ASBP on your screen this week.
Aspire Bio Labs (NASDAQ: ASBP) engages in the business of developing and marketing novel disruptive technology for the sublingual delivery of drugs and other products. Using Aspire’s patent-pending sublingual drug delivery mechanism, drugs:
Are Faster Acting– drugs and other products enter the bloodstream in a minute or two;
Bypass the Digestive Tract- far less of drugs and other products get digested and initial bypassing of the GI-tract can eliminate irritation and adverse reactions;
Are Used Efficiently by the Body: by avoiding a first-pass through the liver drugs avoid being metabolized; and
Are Easier to Take: a small amount of pleasant tasting powder or granules can be taken by those who have trouble with pills and capsules– even someone who is unconscious can be dosed with our products.
Aspire Bio Labs (NASDAQ: ASBP) has developed a novel formulation of sublingual aspirin that increases rapid absorption, eliminates the GI tract side effects, and by-passes first pass liver metabolism resulting in faster peak serum concentration and rapid inhibition of cyclooxygenase (Cox-1). This innovative technology could provide alternative choices in pain care and even help reduce the current opioid epidemic.
Key aspects include:
Patented Delivery System specifically formulated to allow rapid sublingual absorption of aspirin into the blood stream and bypassing the gastrointestinal tract
Fast absorption to help resolve heart attack and stroke
Proprietary formula and manufacturing process
Absorbed instantly in the mouth, which reduces adverse reactions in the stomach (GI tract), not requiring the taking of pills by those who struggle with swallowing.
Large dosage escalation for back pain, arthritis pain, headache, post surgery and cancer pain.
Opportunity:
Large Addressable Market: $80 billion combined analgesics and opioid market
Prescription: Utilizing the FDA 505 (b)(2) Fast Track drug approval process.
OTC: Once the Rx market has been thoroughly established, an opportunity will arise for an OTC product.
First to market: Prescription strength version to be followed by OTC
Proprietary Technology: Enables the ability to pursue broadened applications, using our solubility process, which can be used with other compounds such as supplements.
In February of 2025, Aspire Biopharma, Inc. and PowerUp Acquisition Corp. (Nasdaq: PWUP) successfully merged in a business combination to drive breakthrough innovations in FDA-approved drugs, nutraceuticals, and supplements.The new merged company is called Aspire Biopharma Holdings, Inc. and trades on Nasdaq under the symbol ASBP.
Highlights of the Merger:
Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.
Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel sublingual delivery mechanism to enhance the efficacy of FDA-approved drugs, nutraceuticals, and supplements.
Innovative Drug Delivery Technology: Aspire’s patent-pending delivery system allows rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating rapid metabolizing of drugs and easing tensions on body organs..
Growth and Innovation: Anticipated proceeds from the transaction are expected to further fuel Aspire’s strategic growth plan to accelerate the development of its differentiated pipeline and finance several key therapeutic programs to data announcements.
A Sublingual Aspirin Product
ASBP’s Sublingual Aspirin Product addresses cardiology emergencies and pain management. It is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin, which has been developed by using the company’s patented formulation, and “trade secret” process.
Benefits of “rapid absorption” aspirin are: to stop heart attack and stroke; allow high dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
In the planned initial launch of its sublingual products, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory.
Aspirin is over a century old and is traditionally available in several forms, including effervescence, powder, capsule, and tablet. Over 100 years of documented safety and efficacy data is readily available.
Aspirin is also the only drug in history to receive a certified recommendation by the FDA for heart attack, stroke and colon cancer prevention. However, current aspirin applications are limited due to side effects and the gastric tract.
The Company plans to seek FDA 505(b)(2) Fast Track designation for the prescription strength sublingual aspirin. The 505(b)(2) pathway specifically benefits new drugs that are similar to already approved drugs but have slight variations in formulation or administration routes. Aspire can reference the safety and efficacy data of the original innovator drugs–which are already FDA-approved–accelerating the approval process and reducing associated costs.
The Competitive Edge
ASBP’s sublingual aspirin product, which addresses cardiology emergencies and pain management among other impacts, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. Benefits of “rapid absorption” aspirin are to stop heart attack and stroke; allow high-dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
Commercialization and Go-to-Market Strategy
Launch the sublingual aspirin product initially in the Rx market, followed eventually by an OTC version, with the strategy of creating and preserving greater long-term value.
Partner with an experienced end-to-end marketing and distribution firm. The company is currently evaluating potential partners.
Significant Licensing Opportunity.
Aspire is also developing important non-FDA products with limited regulatory hurdles to come to market sooner, such as a preworkout product and a melatonin-based sleep aid.
Manufacturing
ASBP has entered into a development and manufacturing agreement with a well-known manufacturer–Glatt, based in Ramsey, New Jersey–in the fourth quarter of 2024 to produce sufficient quantities of its sublingual drug product for the clinical trials required to obtain FDA approval to market the product and complete clinical trials.
Although the company believes that Glatt is capable of producing the drug product to support the company’s sublingual aspirin development plan, including its planned clinical trials, ASBP also believes there are a number of alternative third-party manufacturers that have similar capabilities and would be capable of providing sufficient quantities of drug product if necessary.
ASBP has entered into a fill-and-finish agreement with a contract manufacturer to convert sublingual aspirin manufactured by Glatt into packaged drug products that can be utilized in clinical trials and stability testing. The fill-and-finish contract manufacturer will package the aspirin product that has been produced by Glatt into a drug product to be used in the company’s upcoming clinical trials. The company believes that both Glatt and the fill-and-finish contract manufacturer are compliant under current good manufacturing practice, or cGMP, requirements and have experience with cGMP inspections of their respective facilities.
Plans to use the sublingual aspirin manufactured by Glatt to conduct clinical trials to support approval of a section 505(b)(2) New Drug Application (“NDA”). An initial trial will be designed to study the pharmacokinetics of aspirin and its metabolites in blood following sublingual administration of a single dose of each of two different formulations of the Instaprin drug product and a single dose of standard oral aspirin. This initial trial is expected to enroll at least six healthy adult volunteers with each dose separated by a washout period of seven days and will provide information required to (i) select the optimal drug product formulation and (ii) inform the design of a second clinical trial to support FDA approval. The first trial will also demonstrate the relative quickness of Aspire’s sublingual aspirin’s absorption compared to orally administered aspirin tablets. The company plans to design a second clinical trial to demonstrate that sublingual administration of the final selected formulation delivers therapeutic concentrations of drug into the bloodstream, comparable to those of standard oral aspirin, but faster and without gastro-intestinal toxicity associated with oral aspirin. The second trials will also focus on the anti-platelet properties of the sublingual aspirin.
Commercialization
Subject to receiving marketing approvals, ASBP expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, as well as the creation of a dedicated Medical Affairs team to support commercialization efforts. The company believes that such an organization will be able to address the physicians who are the key specialists in treating the patient populations for which its product candidates are being developed. Outside the United States, it expects to enter into distribution and other marketing arrangements with third parties for any of its product candidates that obtain marketing approval.
ASBP also plans to build a marketing and sales management organization to create and implement marketing strategies for any products that it markets through its own sales organization and to oversee and support its sales force.
Since the middle of the month we have seen interest come in to ASBP and the price stabilize over the past few sessions. Watch this one close for a bounce.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND SEVEN HUNDRED FIFTY USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY ASBP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production
ATLX Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure
Some of the company’s high-potential mineral rights are adjacent to or near large lithium deposits that belong to a large, publicly traded comparable that boasts a $1.2 Billion market cap!
Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries
While May has not been an extremely busy month like March and April were but the past 3 weeks have been extremely fruitful.
All 5 of our profiles in May have gone on to make double digit moves after we profiled them. Two of the 5 made MASSIVE and impressive triple digit moves. It has been incredible.
I think that this is a testament to the markets that we are witnessing right now and the impressive rebound that we have seen take place.
The Dow just exploded off of what was a hair above the 52 week low we saw take place exactly one month ago.
We are bringing back a company that is a past winner and has been getting a lot of buzz over the past few months.
Earlier this year we looked at this one when it was sitting around 5.30, before it ran to 6.50 over the next 2 weeks. It is still up slightly from the last time we profiled it a month ago.
Make sure you have ATLX on your right now.
Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.
ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.
The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.
Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.
ATLX holds three key projects that span the major lithium-mineralized zones in LV:
The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;
The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;
The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)
Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production
Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.
The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.
“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”
Cutting-Edge Modular Plant Design
Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:
Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.
Strategic Progress Toward Production
The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.
Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.
Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure
Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.
“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”
Rare Earths: Essential for Defense, Energy, and High-Tech Applications
Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.
Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.
Graphite: A Cornerstone of Battery Technology
Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.
Uranium: Fueling the Energy Transition
Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.
A Diversified Strategy for a Changing World
Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.
“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”
Strategic Partnership with Global Industrial Giant
In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.
Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.
Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.
“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.
Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.
ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.
Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!
This is a Highly Attractive Location:
◼ Resource Potential to Support Large Scale Operations ✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits ✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL
◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place ✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly ✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais
◼ Favorable Infrastructure ✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets
Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.
A Big Neighbor
Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.
Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.
Tiago Miranda
CFO & Treasurer
Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.
Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.
From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.
From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.
Eduardo Queiroz
Project Management Officer (PMO) & Vice President of Engineering
Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.
Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.
Igor Tkachenko
Vice President, Corporate Strategy
Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Nanoviricides, Inc. is close to having a single drug NV-387 for the treatment of all of the “tripledemic” respiratory viruses – Coronaviruses, RSV, and Influenza A, which would be a revolutionary achievement!
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate
The month of May has been incredible for us as I stated in my last email. 2 of our last 4 profiles jumped triple digits on strong interest while the other two ran double digits in the following sessions as well.
You might remember this one from January when it was sitting around the 1.10 level. Since then it has topped out at 1.55 and still holding strong above our profile price.
If you have been a member for a little while then you should go back and look at this one when we profiled it back last July when it doubled in just a few sessions.
Now that we have established that this one has the potential to move let’s dive into the meat and potatoes of what we want to look at for Fridays session.
Pull up NNVC and urgently get it on your screen.
NNVC looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NNVC is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.
NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.
Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..
Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
NV-387 – A novel broad-spectrum antiviral
Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments???????????
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!
Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat – Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics
SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains its drug development strategy to combat important global viral threats.
Measles outbreaks have continued to expand in the US, and the dramatic ten-fold increase in annual Measles cases in Europe last year indicates that Measles will be here to stay. Measles vaccine failure cases have also been increasing according to the European data, which is an important cause for concern. Vaccination rates are falling in developed countries.
In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles virus and disease. There is no approved drug for Measles virus infection.
The Company has already initiated the process for conducting an animal efficacy study that would provide an answer to how effective NV-387 would be against Measles virus.
The Company will make NV-387 available to any licensed physicians intending to treat Measles cases under the Individual Patient Expanded Access protocol of the US FDA. The Company has its own cGMP manufacturing facility.
The Company is pleased to state that it is moving forward with the Phase II Clinical Trial Application (CTA) for the evaluation of NV-387 as treatment of MPox in the Domestic Republic of Congo (DRC). The National Ethics Committee of DRC has recently cleared NV-387 as a potential drug candidate that should advance into the clinical trial, enabling the CTA.
MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of International Concern (PHEIC), a designation it first declared for the MPox epidemic in August, 2024.
This PHEIC is driven by MPox Clade 1a and 1b viruses that are highly pathogenic and highly transmissible. A milder version, MPox Clade 2, caused an epidemic in 2022, and since then became endemic, in certain subsets of populations in the Western World. It is thought that MPox Clade 1a/1b viruses could possibly lead to a wider epidemic including the rest of the world beyond Africa.
There is currently no approved drug for the treatment of MPox infection. A drug, tecovirimat, (TPOXX®, SIGA) failed in clinical trials for the treatment of MPox. TPOXX has been approved for Smallpox in the USA under the FDA “Animal Rule” and continues to be stockpiled by the US Strategic National Stockpile. A broad-spectrum antiviral effective against all orthopoxviruses including MPox and Smallpox is needed.
“NV-387 is a revolutionary antiviral drug that can combat many viral infections,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, “We are advancing it rapidly towards establishing human clinical effectiveness data and regulatory approvals. We believe our MPox and Measles work will enable rapid advancement of the drug, and make a great global impact in large markets fulfilling unmet medical needs.”
The Company is also developing NV-387 as an “emperic” treatment of respiratory viral infections. We are developing a clinical protocol for a “basket-type” clinical trial, i.e. evaluating a single drug, namely, NV-387, against many viruses within a single clinical trial.
The focus of this proposed clinical trial will be on All Influenzas, All Coronaviruses, and RSV. If successful, this study would enable NV-387 to be prescribed immediately when a patient presents to the physician with a respiratory infection suspected to be viral, without waiting for test results to determine which viral infection it is.
Additionally, the Company is developing a pan-herpesvirus drug, NV-HHV-1. Herpesvirus infections from HSV-1, HSV-2, VZV, EBV, as well as HHV-6 have been linked to neurological damage that can eventually lead to Alzheimer’s disease. An effective drug that can eradicate herpesviruses is an unmet medical need. Such a drug can make a major impact on chronic diseases such as Alzheimer’s.
To date, only effective drugs have brought or maintained endemic or circulating viruses under control. There are no vaccines for herpes viruses, HIV or hepatitis C virus. Yet, successful drugs have helped patients to be cured (HCV), or recover from episodes (HSV), or at least maintain healthy lifespan (HIV) without any vaccines.
Market sizes for effective antiviral drugs run into several billions of dollars for each indication. Also, market sizes expand rapidly once an effective drug is introduced.
“NanoViricides is poised to revolutionize how we treat viral infections, just as antibiotics revolutionized treatment of bacterial infections,” said Dr. Diwan, adding, “We continue to march forward and strive hard to make this bright future a reality and to make a meaningful impact on public health, chronic diseases, and individual patients.”
Measles cases in Europe were over 35,000 in 2024, an almost ten-fold increase from 2023, according to the annual report of European Center for Disease Prevention and Control(ECDC). Only approximately 87% of cases were in unvaccinated persons, and 13% of the cases were of vaccine failure, out of the cases with known vaccination status.
The significant Measles vaccine failure rate observed in Europe is alarming, considering that the two-dose vaccine is supposed to be 97% effective. Overall, childhood vaccination was about 94% and declining. This rate is below the 95% considered the threshold for achieving “herd” or community immunity.
Given the various causes of vaccine failure, and of vaccine hesitancy, attaining 95% vaccine coverage cannot be considered a very probable solution to combating the Measles epidemic. An effective drug is needed to combat the epidemic.
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.
An “opinion and analysis” article published in Scientific American on February 7th correctly recognizes that the H5N1 “virus is versatile…and mutating”, although it rapidly devolves into unwarranted and unsubstantiated inflammatory and false assertions against the Trump administration (https://www.scientificamerican.com/article/the-us-is-not-ready-for-bird-flu-in-humans/).
This article’s titular declaration that the “US is not ready for bird flu in humans” is myopic.
We beg to differ from this opinion, and hereby declare that our broad-spectrum antiviral drug NV-387 that H5N1 virus will not be able to escape even as it changes in the field, is ready to fight the battle and save lives, should a human H5N1 pandemic occur.
The said article is basically an opinion that is clearly limited to partial and biased analysis of current drugs and vaccine efforts for H5N1, and demonstrates total unawareness (or ignorance) of the failures (or very limited successes) of antiviral vaccine, antibody and small chemical drug approaches during the COVID pandemic. To wit, during COVID pandemic, vaccinated persons were still infected with the virus because the virus was ever-changing, and they became unwitting carriers of the virus. Thus, vaccination did not break the chain of virus transmission, and the R0 number continued to increase throughout the pandemic despite compulsory vaccinations. The immunity from vaccines was not long-lasting, and now immunity from natural COVID infection is thought to have been superior to that provided by the vaccines.
“Vaccines are not the right response for fast-moving viruses such as SARS-CoV-2 or H5N1, because vaccine deployment is at least 12 to 15 months behind the virus, when the virus has already moved on,” commented Anil R. Diwan, PhD, adding “We must learn from past pandemics and past mistakes. We believe that the iconoclastic Trump 2.0 administration will heed these lessons.”
NV-387 is ready to be a significant part of the pandemic preparedness and response arsenal, because it has already demonstrated activity against different and varied viruses including Coronaviruses (COVID), Influenza viruses, RSV, and even Poxviruses (MPox/Smallpox). Its design is thought to enable this drug NV-387 to be able to fight as many as 90-95% of human pathogenic viruses, based on literature reports of the vulnerabilities of human pathogenic viruses.
The bird-flu virus and its variants are highly unlikely to escape the broad spectrum, host-mimetic, antiviral drug NV-387, because all of these variants continue to land on the same host-side feature that NV-387 mimics. Further, in stringent lethal animal model studies to treat Influenza A H3N2 infection, NV387 has shown superior activity compared to osletamivir (Tamiflu®), peramivir (Rapivab®), and baloxavir (Xofluza®); all of these approved small chemical drugs are prone to escape by the virus with just single point mutations.
“We believe that the new administration will focus on rapid development and acquisition of broad-spectrum therapeutic drugs like NV-387 that the virus cannot escape, for the Nation’s arsenal of antiviral weaponry, in order to prepare for not just a potential bird flu pandemic in humans but also potential spread of MPox outside of the African region, and potential Smallpox bioteerorism, all at the same time, with a single drug capable of fighting all of these fights, thus saving billions of dollars to the American taxpayer, instead of the failed strategy of chasing viruses by continuing to develop new multi-billion-dollar vaccines every few months that was adopted by the Biden administration in response to the COVID pandemic,” Dr. Diwan stated.
Vaccines will now also face an increased barrier of being able to win over people to voluntarily take the vaccine shot that the people already know offers limited protection because so many people experienced a COVID infection multiple times even after getting vaccinated, due to variants.
“The Biden administration propagated only vaccines and antibodies development under the COVID response and later Project NextGen funding. This was in spite of the fact that antibodies, although rapidly given emergency use authorizations by the FDA, were losing efficacy every few months, as soon as a new variant of SARS-CoV-2 appeared. And yet the Biden administration continued to chase the changing virus with new vaccines and new antibodies, resulting in an extremely costly approach with little to show for it. Despite this, under the Biden administration, HHS has already sent $590 million of taxpayer money to Moderna alone, among other vaccine funds recipients, in order to be prepared to be able to develop an accurate H5N1 vaccine if and when a pandemic occurs, even though the virus will be different from any that the $590 million are being spent on,” said Diwan.
“I am certain the Trump 2.0 administration is in no mood to entertain such wasteful expenditures for H5N1 bird flu response,” said Dr. Diwan, adding, “Everyone understands that a broad-spectrum drug that the virus cannot escape is an essential part of an excellent multi-pronged strategy for pandemic response.”
“I implore the HHS Secretary nominee Robert F. Kennedy Jr. to take the lessons of COVID pandemic to heart, and produce a consummate response to Bird Flu. Just as the Trump 1.0 administration deployed Operation Warp-Speed to enable development of the first ever modern mRNA vaccine rapidly, a similar approach needs to be adopted to promote rapid development of new therapeutic drugs against bird flu that the virus would not escape, so that there is an arsenal of weapons against the virus to treat the infection and save lives, while there is still time,” Diwan said.
Two different major genotypes of bird flu H5N1 are found to be circulating, both of which have caused infections in humans. A highly pathogenic genotype D1.1 from birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans. A somewhat less pathogenic genotype B3.13 from dairy cows in several states including California has infected dairy workers that have recovered. In addition, D1.1 was recently found in milk from dairy cows in Nevada. Both genotypes are also found to be infecting many other mammals including cats, dogs and pigs. Dairy workers, persons exposed to wild birds or free-range flocks, and even veterinarians have been infected with bird flu.
Fortunately, there is no strong evidence of human to human transmission yet. Therefore, the threat of potential pandemic is still considered to be low. However, scientists have already found that a single point mutation in this virus can change that scenario quickly. Thus, the urgency of developing a viable broad-spectrum antiviral drug response is now immediate.
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”) today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared for further regulatory filing of a complete Clinical Trial Application (“CTA”).
“We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of MPOX disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company.
The Company previously announced in January, 2025 that it has engaged a CRO for conducting a Phase II clinical trial to evaluate the safety and effectiveness of NV-387 for the treatment of MPox in the African Region.
Subsequently, the CRO has engaged the Medical Hospital at the University of Kinshasa as the clinical trial site (the “Site”) for the Phase II clinical trial.
Thereafter, the Company, the CRO, and the Principal Investigator at the Site have developed a package of information comprising synopses of the clinical trial protocol, and required background information on the novel drug NV-387, including a draft summary report of the Phase I human clinical trial, prior non-clinical data, as well as summary of the animal model effectiveness and safety of NV-387 for the treatment of lethal MPox infection providing rationale for the use of the novel broad-spectrum antiviral drug NV-387 for the treatment of hMPXV viral infection and the MPox disease caused by the infection.
This summary package was submitted to the National Regulatory Agency’s Ethics Committee CNES for a first review towards approval to proceed to the preparation and submission of the detailed CTA to the National Regulatory Agency, namely MSP of DRC.
The approval that we have now received from CNES clears the path for the perfected CTA filing to the MSP for approval and start of the clinical trial.
There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024.
“NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”
NV-387 was found to be highly effective in increasing survival in lethal animal models of influenza virus, surpassing existing drugs Tamiflu®, Rapivab® and Xofluza® by a large margin.
NV-387 led to a complete cure of lethal RSV lung infection in an animal model study. There is no approved drug for RSV treatment.
NV-387 was found to be highly effective in increasing survival in lethal animal models of Coronavirus infection (a stand-in model for SARS-CoV-2 infection), surpassing existing drug remdesivir by a large margin.
NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.
In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.
Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.
Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.
In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.
MPox disease, caused by the human MPox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the WHO African Region that includs the Democratic Republic of Congo (DRC), Uganda, and other countries. It led to the WHOdeclaring a Public Health Emergency of International Concern (“PHEIC”) on August 14, 2024. Since then, the PHEIC status declaration has been extended twice, most recently in March, 2025. The Mpox epidemic has continued to spread in the DRC, Uganda, and neighboring countries and the number of new weekly cases is still increasing in the WHO African Region.
NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.
Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.
New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND NINE HUNDRED FIFTY USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
DEVS is the firstand only pure-play carbon-credit company to list on a major U.S. exchange
DEVS has more than 140 projects in its pipeline, with more than a dozen signed contracts representing an opportunity to generate 30 million+ credits per year
Polar Asset Management Partners Inc. Acquires Stake in DevvStream Corp
DevvStream Adds Hydroelectric Power Facility to its Asia I-REC Program
****DevvStream Corp and Fayafi Investment Holding Sign MoU to Explore Creation of “Fayafi x DevvStream Green Ventures” to Accelerate Global Sustainability Investments ****
We are back with another profile that is getting a ton of attention this week after dropping explosive news.
This one hasn’t seen this type of interest since the last time we profiled it back in March.
Pull up DEVS right away. You want to make sure you research this one thoroughly and read everything we have to say before you start your own due diligence.
This one has been getting a lot of attention over the past two sessions after dropping some substantial news that we are going to get into.
DevvStream just signed a game-changing Memorandum of Understanding with Fayafi Investment Holding — one of the UAE’s most forward-thinking investment platforms, to launch a global joint venture called Fayafi x DevvStream Green Ventures.
This joint venture is backed by an initial funding commitment of $100 million and is built to deploy capital into climate infrastructure projects around the world, especially in fast-growing, underserved regions.
DevvStream will own 20% of the venture and serve as the operational and technical lead, unlocking revenue from environmental asset generation and from the returns on these investments. DEVS will be able to make money from both the environmental assets they generate and the returns from the investments through their percentage ownership of the JV.
With this structure, DevvStream gains direct access to the Middle East, a region with a massive need for carbon credits, thanks to the carbon-intensive nature of the oil and gas industry.
The combination of Fayafi’s institutional network and capital with DevvStream’s execution engine could prove incredibly powerful, creating a scalable platform for environmental impact and value creation.
And with over 140 projects already in the pipeline, DevvStream’s momentum doesn’t appear to be slowing down anytime soon.
If you really want to understand DEVS you need to understand what carbon credits are. They are a financial tool designed to help organizations advance decarbonization efforts by funding environmentally conscious projects. The carbon market is already a $1T market according to many reports which also expect it to double over the next 4 years or so.
DevvStream Corp and Fayafi Investment Holding Sign MoU to Explore Creation of “Fayafi x DevvStream Green Ventures” to Accelerate Global Sustainability Investments
MAY 7, 2025 11:30AM EDT
Proposed capital-light joint venture aims to unlock high-impact decarbonization and energy transition opportunities
Calgary, Alberta–(Newsfile Corp. – May 7, 2025) – DevvStream Corp. (NASDAQ: DEVS) (“DevvStream” or the “Company“), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced that it has signed a Memorandum of Understanding (“MoU“) with Fayafi Investment Holding (“Fayafi“), one of the UAE’s most forward-thinking and diversified investment platforms. The agreement outlines the intent to launch Fayafi x DevvStream Green Ventures, a global joint venture designed to accelerate investment in decarbonization and climate infrastructure projects worldwide.
Fayafi x DevvStream Green Ventures is expected to combine DevvStream’s operational and technical expertise with Fayafi’s capital resources, institutional network, and ESG-focused investment strategy. The platform would focus on identifying, funding, and scaling a pipeline of environmental projects across high-growth regions. Firm agreements are expected in Q2 2025, with initial project deployments targeted for Q3/Q4 2025. The initial funding commitment is expected to be $100 million, with the potential to scale significantly based on project performance and capital deployment efficiency.
“Fayafi x DevvStream Green Ventures is envisioned as a purpose-built platform to meet the needs of climate and energy transition investment in a changing world,” said Carl Stanton, Chairman of DevvStream. “Fayafi, as a strategic and financial partner, represents an ideal counterpart to help us scale quickly and responsibly, providing significant upside to DevvStream investors.”
Bobby Campbell, the Chief ESG Investment Officer for Fayafi Investment Holding added, “This MoU marks an important step toward the future of climate finance. We believe in the potential of this partnership and are committed to continuing the dialogue with DevvStream.”
The joint venture will be structured as an independent entity, with ownership expected to be allocated 80% to Fayafi and 20% to DevvStream, and economics shared on a pro-rata basis. This capital-light model enables DevvStream to expand its global presence in energy transition and environmental assets while unlocking recurring revenue streams from project management, consulting, and carbon monetization—with minimal upfront investment.
Fayafi will serve as the financial and strategic engine of the venture, leveraging its institutional relationships and global network to drive market access, regulatory approvals, and execution at scale. The MoU also grants DevvStream exclusivity during the feasibility phase and a first right of refusal on carbon-related opportunities, underscoring a shared commitment to long-term alignment and disciplined project selection.
As operational and technical lead, DevvStream would be responsible for identifying and evaluating high-impact sustainability projects, structuring and registering environmental assets under global standards, managing implementation, and overseeing the full lifecycle of carbon credit generation and monetization. Fayafi’s role as financial sponsor and market enabler would complement DevvStream’s execution, supporting efficient scaling into undercapitalized markets.
This proposed joint venture marks a pivotal step in DevvStream’s strategic evolution, allowing the Company to expand its footprint, enhance monetization pathways, and deliver scalable climate impact through a collaborative global platform.
About Fayafi Investment Holding
Fayafi Investment Holding Limited is a global investment platform headquartered in Dubai, UAE, with a diversified portfolio across sustainability, AI, defense, biotech, and real estate. As the first UAE-based company listed on the Vienna Stock Exchange and the issuer of a bankable certificate under the SIX Swiss Exchange, Fayafi is widely recognized for its innovative, long-term investment philosophy and commitment to ESG leadership.
______________
DEVS isa leading authority in the use of technology in carbon project development.
The company’s mission is to create alignment between sustainability and profitability, helping organizations achieve their climate initiatives while directly improving their financial health.
The company is involved in a number of green initiatives with the ultimate goal of reducing the impact of climate change.
DEVS works with governments and corporations worldwide to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissioBns, and sequester carbon directly from the air. DEVS also helps these organizations meet their net zero goals by providing them access to high-quality carbon credits.
What they do is partner with companies that have technologies that are eligible for generating carbon credits, producing the credits on their behalf.
DevvStream then gets 25% of the credits that are generated for the life of the project. This has the potential to be highly lucrative since the company isn’t investing in the project itself.
The company has more than 140 of these projects in its pipeline, with more than a dozen signed contracts representing an opportunity to generate 30 million+ credits per year.
Over the past year, the company has announced several signed contracts with EV charging networks to help them generate carbon credits. These include:
Texas-based Go-Station
New York City-based Green Energy Technology
India-based E-Fill Electric
Florida-based OK2Charge
DEVS entered into agreements to stockpile carbon credits, including 1.2 million credits for conservation of 200,000 hectares of Amazon territory and 2.5 million credits “selected from a field of over 120 million potential carbon credits from dozens of other projects.”
Another major development was there of a 50% equity stake in Monroe Sequestration Partners (MSP) and its carbon sequestration operations.
MONROE PROJECT
Project Revenues are expected to be generated from:
• Storage fees from accepted CO2 to be sequestered
• Up to 260M 45Q Tax Credits
• Sale of up to 260M carbon credits
45Q tax credits are generated via a US tax credit program that incentivizes carbon capture, utilization, and storage (CCUS) projects • 45Q tax credits are transferable and are valued at up to $85 per ton of CO2 stored.
I-REC
Late last year, DEVS announced that it will be diversifying its revenue streams to include renewable energy certificates (I-RECs).
An I-REC is generated when a power plant generates 1MWh of renewable energy. It can then be sold to companies that need them to maintain their commitments to renewable energy.
These days, some of the largest companies in the world — heavyweights such as Apple, Google, Microsoft, and Samsung — have commitments to use 100% renewable energy, which often requires buying I-RECs. DevvStream has secured exclusive agreements in Asia’s renewable energy market: Medellin Solar Power Facility (Philippines): A 730 MWp project capable of generating over 1.2 million I-RECs per year. PT.Siteba Hydroelectric Facility (Indonesia): An already operational hydro facility expected to generate I-RECs in 2025
Polar Asset Management Partners Inc. Acquires Significant Stake in DevvStream Corp
Transaction Overview
Polar Asset Management Partners Inc. recently executed a notable transaction by acquiring 558,415 shares of DevvStream Corp on December 31, 2024. The shares were purchased at a price of $0.752 each, marking a strategic move by the firm. This acquisition represents a new holding in Polar Asset Management’s portfolio, with DevvStream Corp now accounting for 0.01% of the firm’s total investments. The transaction reflects Polar Asset Management’s interest in expanding its portfolio within the technology and environmental sectors.
Polar Asset Management Partners Inc is a well-regarded firm known for its expertise in value investing. The firm manages an equity portfolio valued at $3.44 billion, with significant investments in the Financial Services and Technology sectors. Some of its key holdings include Sprott Physical Gold Trust, Sprott Physical Silver Trust and Insulet Corp. The firm’s strategic investment decisions are guided by a focus on long-term value creation and market opportunities.
DevvStream Announces Additional Investment
PUBLISHED
MAR 19, 2025 9:00AM EDT
Investment by Chairman Carl Stanton and Director Wray Thorn reinforces confidence in DevvStream’s mission
Calgary, Alberta–(Newsfile Corp. – March 19, 2025) – DevvStream Corp. (NASDAQ: DEVS) (“DevvStream” or the “Company“), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, energy transition, and innovative carbon management solutions, today announced that Carl Stanton, Chairman of DevvStream, and Wray Thorn, Director, have invested an additional $218,000 into the Company’s 5.30% Secured Convertible Note, due November 2026.
The funds support DevvStream’s ongoing efforts to expand into energy transition markets, grow its partnerships and solidify its position as a leader in the carbon offset market. Stanton and Thorn are also co-founders of Focus Impact Partners.
DevvStream Boosts Carbon Offset Initiative Through E-Commerce Partnerships
PUBLISHED
MAR 18, 2025 9:00AM EDT
Partnering with e-commerce agencies, technology integrators, and 3PL providers to drive adoption of its D-PIVOT carbon offset tool across Shopify storefronts
New agreements with Zing (e-commerce marketing/software) and Minimus Fulfillment (3PL for celebrity and creator brands) strengthen DevvStream’s leadership in the carbon offset market
Calgary, Alberta–(Newsfile Corp. – March 18, 2025) – DevvStream Corp. (NASDAQ: DEVS) (“DevvStream” or the “Company“), a leading carbon credit project co-development and generation firm specializing in technology-based solutions, today announced a major expansion of its e-commerce sustainability strategy through partnerships designed to accelerate adoption and revenue growth for its previously announced DevvStream Personal Impact Voluntary Offset Tool (“D-PIVOT“).
D-PIVOT is a free Shopify-integrated software tool that enables consumers to offset the carbon footprint of their online purchases by supporting verified, high-integrity environmental projects, including clean water access, rainforest preservation, and indigenous-led conservation programs. It is made available primarily through wholesalers, fulfillment providers, and distributors, allowing businesses to offer a seamless sustainability solution for environmentally conscious customers. D-PIVOT can be found at https://apps.shopify.com/carbon-emissions.
By forming strategic partnerships with e-commerce marketing agencies, technology integrators, and third-party logistics (“3PL“) providers, DevvStream is positioned to drive rapid scale across the Shopify ecosystem, which powers approximately 28% of all online stores in the United States. This also provides the Company with a strong sales channel for its inventory of several million high-quality carbon credits.
Strategic Market Opportunity: Tapping into High-Growth E-Commerce Sectors
E-commerce continues to be a dominant force in U.S. retail, with logistics, marketing, and technology integration services growing at an accelerated rate. This represents a major revenue opportunity for DevvStream:
Third-Party Logistics Providers: The U.S. 3PL market generated approximately $299.5 billion in gross revenue in 2023, with projections exceeding $350 billionby 2030. Parcel shipments are growing by 5% annually, creating an ongoing need for sustainable shipping solutions.
E-Commerce Marketing & Media Agencies: The U.S. digital advertising agency market is expected to generate $52.4 billion in revenue in 2024, up 10.3% year-over-year, reflecting continued investment in e-commerce brands.
With D-PIVOT, DevvStream is positioned to capitalize on these trends by embedding sustainability into online transactions at scale.
Partnerships with Zing and Minimus Fulfillment: Scaling DevvStream’s Reach Across Shopify
To accelerate market penetration, DevvStream has signed agreements with two leading companies. These partnerships are expected to facilitate the introduction of D-PIVOT to online retailers looking to enhance their sustainability efforts.
Zing, an e-commerce marketing and software development company, provides access to a diverse portfolio of online brands seeking sustainability integrations.
Minimus Fulfillment, a leading 3PL provider serving high-profile clients, provides DevvStream with access to retailers actively looking for sustainability-friendly shipping solutions.
“Partnering with Zing and Minimus Fulfillment represents a major step forward in our mission to make carbon offsetting accessible at the point of purchase,” said Sunny Trinh, CEO of DevvStream. “With e-commerce reshaping consumer habits, this initiative enables us to scale revenue while embedding sustainability into everyday transactions. By collaborating with key players in the online retail ecosystem, we can scale D-PIVOT’s impact and empower businesses to offer meaningful climate action to their customers.”
“At Zing, we work with a diverse portfolio of e-commerce brands that are constantly looking for innovative ways to enhance customer experience and align with consumer values,” said Dan Melnick, CEO and Co-Founder of Zing. “Integrating DevvStream’s D-PIVOT solution allows our clients to offer seamless carbon offset options at checkout, adding both sustainability and customer engagement benefits. DevvStream’s expertise in high-integrity carbon credits makes them the ideal partner for this initiative, ensuring that the offsets are both impactful and transparent.”
“Minimus Fulfillment is excited to be working with the D-PIVOT Shopify plugin to offer it to our fulfillment clients,” said Paul Shrater, CEO of Minimus Fulfillment. “We enjoy sharing unique opportunities that can enhance our client’s businesses as we view them as client-partners and not just as a client/vendor relationship. Consumers, more so than ever, are looking for ways to feel an emotional connection to the brands they purchase from, and by providing a way for them to offset the carbon footprint of their purchases, brands can bring this experience to their customers in a trusted way, utilizing highly vetted carbon credits from a plugin developed by the only carbon credit company that is public on the Nasdaq exchange.”
As co-founder and CEO, Sunny is responsible for building and executing DevvStream’s project pipeline through his vast network of sustainable technology and corporate relationships. He has spent over 25 years in the technology sector and directly in developing new verticals in ESG and carbon markets.
He also serves as the Chief Digital Alchemist for Devvio Inc., where he develops new business models in the ESG and carbon markets. Prior to DevvStream, Sunny led innovation as VP of Ecosystem at Avnet Inc. (AVT: NASDAQ). He was also the COO for Jooster and VP of Sales for Arrow Electronics (ARW: NYSE) where he led the design team for a Corvette driven by a quadriplegic.
Sunny served as CEO for 9:Fish Surfboards and was an adjunct professor for Cal Lutheran University’s MBA program where he started the school’s technology tract. Sunny holds a B.S. and M.E in Engineering, an M.B.A. degree, and holds several patents on electronic accessories for cell phones.
David Goertz
CHIEF FINANCIAL OFFICER
David provides accounting, assurance, taxation and business advisory services to private and public companies, not-for-profit organizations and incorporated professionals. David has specialized knowledge of the manufacturing, mining, real estate, and technology industries. He also has a keen understanding of public company operations, restructurings, acquisitions and IPOs.
Chris Merkel
CHIEF OPERATING OFFICER
Chris is the VP and Chief Operating Officer of DevvStream. Prior to joining the team, Chris spent 24 years managing strategic customers, growing technical services verticals and held sales leadership roles at Avnet (AVT: NASDAQ) and Arrow Electronics (ARW: NYSE). He has engaged with companies at every stage, from pre-funded startups to global enterprises in markets such as IIoT, consumer, industrial and medical. Additionally, Chris spent 5 years with Sierra Pacific Industries in a general sales and operations management role. He has over 30 years of sales, operations and general management experience successfully managing diverse teams and projects.
Jonathan Miller
CHIEF COMMUNICATIONS OFFICER
An accomplished communications professional with over 20 years of experience developing integrated marcom programs, Jonathan specializes in the automotive, robotics, consumer electronics, sustainability/ESG, and semiconductor domains.
With expertise in brand identity, web design, video development, copywriting, print/layout, public relations, and event management, Jonathan has held several senior positions in the Silicon Valley area, most recently with Ambarella (Nasdaq: AMBA), a leading provider of AI vision processors for edge applications. Prior to that, Jonathan was VP of Advanced Products for a consumer electronics startup whose technology patents were ultimately purchased by Facebook. He was an eighth-grade English teacher for seven years in the Oakland Unified School District and received his bachelor’s degree from Stanford University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY DEVS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
USAU is Sitting on 44 million AuEq Proven & Probable oz Reserve!
Roth Capital Partners recently initiated coverage of the company with a Buy rating and a price target of $10, calling the company “undervalued” based on its CK Gold Project
USAU is sitting on $9.1 Million in Cash as of 1/31/25
USAU increased from $4.18 to $10.40 over the past year, a 149% increase while the market cap increased from $45 million to $132 million, a 193% increase (We have been updating since $6)
We have one of our top profiles over the past 6 months is back front and center for tomorrow’s session.
Our last Nasdaq went crazy. It opened Thursday at .96 and by Monday it was 1.23.
This next one has been hovering and testing the 11 dollar as of late which is incredible since we have been covering this one since November when it was sitting in the 6’s.
This has been a great environment for Gold. Physical gold, gold stocks, gold ETF’s etc. have all been performing well. Gold giant Newmont Mining is up roughly 50% in 2025, among other big gold companies that are performing well.
We just hit an all time high last month and gold has been getting a tremendous amount of attention.
Back the the company in question. You will remember it.
We brought it to you back in November when it was sitting around 6.20.
Then we showed it to you again in mid January when it was a little over 7.50.
In early Feb again we said you should research this company while it was still under $8.
We reminded you again a few weeks ago about USAU.
Since then we have seen this company top out at the 52 week high of 11.75 and is flirting with 11 bucks again right now.
Pretty good right?
USAU is sitting strong, hovering right around the 11 buck mark right now.
Why all the buzz about USAU? That really cannot be summed up in a sentence but there is no denying that this has been a “right place, right time scenario”.
Roth Capital Partners recently initiated coverage of the company with a Buy rating and a price target of $10, calling the company “undervalued” based on its CK Gold Project.
Paradigm Capital also had positive coverage, with a Speculative Buy rating and a target price of $16.50. Paradigm’s analysts highlighted that the CK Gold Project, now fully permitted and shovel-ready, is positioned to become Wyoming’s next major gold and copper mine.
We also saw HC Wainwright raise their price objective on U.S. Gold from $11.00 to $13.00 and gave the stock a “buy” rating in a research report In late November.
USAU is also sitting in the portfolio of significant Wall Street players like JP Morgan Chase & Co, Jane Street Group, Prospera Financial Services & Geode Capital Managment to name a few.
Commonwealth Equity Services LLC purchased a new stake in U.S. Gold Corp. in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 31,000 shares of the technology company’s stock, valued at approximately $190,000.
Gold has been constantly in the news cycle over the past few years now since inflation started running wild.
Many top analysts are saying that gold stocks are poised to perform well in 2025 due to a combination of global economic uncertainties, inflationary pressures, and a stable demand for safe-haven assets. Inflation concerns continue to exist, pushing investors toward gold as a store of value. Geopolitical tensions and economic volatility create an environment where gold remains an attractive hedge against risk. As demand for gold remains strong and production becomes more efficient, gold companies offer a compelling investment opportunity for those seeking exposure to the precious metal while benefiting from the potential upside of well-managed mining operations.
U.S. Gold Corp. (NASDAQ: USAU) is an emerging gold and copper exploration and development company positioned to benefit from the ongoing bull market in gold.
The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho.
With a focus on shovel-ready projects and a strategic location in a mining-friendly jurisdiction, U.S. Gold Corp aims to capitalize on rising gold prices. The company generates revenue primarily through the development of its mineral assets, particularly the CK Gold Project in Wyoming.
This project is one of the few permitted and shovel-ready gold and copper endeavors in North America, allowing for a streamlined path to production!
The company’s Keystone project in Nevada is very unique. It is a standalone district-scale project, located near Barrick’s flagship Cortez complex. It has very similar geology and stratigraphy to its neighbor, Cortez. It is USAU’s belief that a number of significant gold deposits are hosted at Keystone, and it is eagerly awaiting market conditions to improve so that we can explore Keystone with the level of interest that it deserves. It is a company maker in its own right.
U.S. Gold Corp plans to leverage its gold and copper reserves to maximize profit margins. With rising gold prices and stable energy costs, the company stands to benefit significantly as market conditions favor gold mining operations.
U.S. Gold Corp. Provides CEO Update – April 2025
CHEYENNE, Wyo., April 30, 2025 /PRNewswire/ — U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (Nasdaq: USAU), a U.S.-focused gold and copper exploration and development company, is pleased to provide the following update:
Full Steam Ahead!
Dear Shareholders,
Thank you for your continued support as we move the Company forward. Coinciding with our Annual Meeting of Stockholders held on April 28th, I am taking the opportunity to update you on the advances we’ve made, continue to make and what you can expect in the coming weeks and months.
Highlights
Financial Performance
Share price increased from $4.18 to $10.40 over the past year, a 149% increase.
Market capitalization increased from $45 million to $132 million, a 193% increase.
Growth supported by the February 2025 updated prefeasibility study and the receipt of full permits for the CK Gold Project.
The Company raised $10.2 million in November 2024.
Treasury strengthened through the ongoing exercise of warrants.
CK Gold Project
Fully permitted as of November 2024.
February 2025 prefeasibility study shows strong project economics at conservative metal prices ($2,100/oz gold, $4.10/lb copper).
Located near Cheyenne, Wyoming, with access to skilled labor, contractors, and transportation infrastructure.
Project strategy includes mitigating tariff exposure by prioritizing American-sourced materials and equipment.
Receiving interest from debt providers and concentrate buyers; the Company is focused on minimizing shareholder dilution.
Final feasibility study work expected to begin in late May 2025, with targeted completion in Q3 2025.
Financial Performance
Additional reconnaissance work planned around the CK Gold Project, with deeper drilling postponed for strategic reasons.
Keystone Project continues to present opportunities for near-surface oxide and deeper sulfide mineralization; awaiting exploration capital or partnership.
Challis Gold Project exploration activities can commence with bond in place; awaiting exploration financing or partnership.
Financial Performance
Just one year ago, our company’s share price was $4.18 with a market capitalization of $45 million. Today, as I pen this message, our shares are trading at $10.40 each, and our market cap has soared to $132 million, an impressive 149% and 193% increase, respectively. While the rise in gold and copper prices has undoubtedly played a role in this growth, it is our updated CK prefeasibility study released on February 11th, 2025, along with securing a full permit to begin construction on the project that continues to bolster our valuation. Despite the ongoing challenges in the resource sector and low valuations in general that do not align with industry norms, we are heartened to see the market beginning to recognize U.S. Gold’s potential. We are committed to maximizing this potential and delivering value to our shareholders.
The CK Project
As mentioned above, the project is now fully permitted as of November 2024 and showing outstanding economic metrics at conservative metal prices, where studies were pegged at $2,100 per ounce gold, $4.10 per pound copper, and $27 per ounce silver. The sensitivity table in the February 2025 prefeasibility study indicated that at $3,000 per ounce gold and $4.50 per pound copper, the CK Gold Project could represent an exceptional opportunity. We believe the CK Project, projected to produce gold and copper, promises a truly remarkable opportunity that helps meet the current U.S. administration’s desire for homegrown domestic critical mineral production.
The CK Project is strategically located just 20 miles from Cheyenne, WY, and 100 miles from Denver, CO, placing it in the heart of a mining hub with access to a skilled local labor pool, including contractors, and fabrication shops. By sourcing materials and equipment locally, the project benefits from competitive pricing and supports the surrounding community. Additionally, the project’s proximity to major transportation networks (interstate highway and rail) eliminates the need for man-camps or transportation issues, which further enhances the economic viability of CK.
However, the project is not immune to the impact of tariffs impacting its initial capital. With mechanical equipment and steel projected expenditures accounting for approximately 28% of the initial capital, not all of which is foreign sourced, the project faces limited exposure to the impact of potential tariffs on foreign goods. To mitigate this risk, we are prioritizing American-made products and materials wherever possible. By focusing on domestically sourced items, along with labor and energy costs, the project is positioned to navigate the uncertainties of tariff negotiations and continue to thrive in a competitive market.
Financing risk is likely top of mind for investors and the fear of equity dilution. I am pleased to share that the Company is already receiving interest from debt providers, and those interested in securing our expected high precious metal content copper concentrate projected to be unaffected by penalty elements. We see avenues to secure significant debt financing and we can apply this to a project that is expected to pay back in two years or less.
Management and insiders, along with a cadre of supportive shareholders who believed in the CK Project from the outset, have an all-important stake in the success of the project. We are aligned by a common interest to avoid unnecessary dilution, and we are working on illuminating the benefits of CK to the market in anticipation of continued increased interest and shareholder value. Furthermore, last November, the Company raised $10.2 million and since then the exercising of warrants has been reinforcing treasury, so the Company is well positioned through to project financing. With much of the necessary groundwork already completed and our burn rate relatively low, further enhancing our financial stability. Rest assured, we have a priority to limit shareholder dilution and are well positioned for future success.
Feasibility Study (FS) work is set to commence following the completion of additional ongoing optimization work. While we adopted conventional froth flotation for the PFS, we still hold out hope for opportunity in two areas in the plant design. Firstly, we should have definitive tests on alternative flotation technology which offers the prospect of improved recovery, smaller plant footprint and lower operating cost. Test work on this opportunity concludes in early May. Secondly, we have evaluated continuous filtration equipment, rather than batch filtration equipment, and successfully obtained the desired moisture content for dry-stack tailings placement. The FS will finalize the equipment selection to optimize the plant, with final FS work commencing in late May, for a targeted completion in Q3 2025.
Exploration
At CK there remains opportunity around the current mineral reserves and resources, and we know that the current mineral resource is “drill limited”. We will do additional reconnaissance work around the current project area but will postpone proving up the additional mineral reserves and resource at depths below and to the southeast of the currently planned pit to maximize our investment dollars.
Keystone holds the potential of being a world-class, tier 1 district-scale opportunity currently waiting for exploration capital or a partnership to unlock its full potential and take advantage of the attractive exploration opportunity it presents. Remote spectral sensing work revealed additional targets to the south of the Company’s 20-square mile holding that have only had some initial surface grab samples taken that show near surface oxide mineralization. Keystone offers two opportunities, near surface oxide potential and deeper high-grade sulfide mineralization. The Company has an approved plan of operations for exploration on several sites, and we await the right opportunity to investigate some very promising exploration targets.
At Challis we have revived a prior plan of operations and have put a bond in place to allow exploration activities to commence. As with Keystone, Challis awaits exploration financing and capacity to pursue an exploration program either in-house or with a partner. Our laser focus is on CK for now, but a pivot back to realize the Company’s significant exploration opportunities is not forgotten, merely waiting for the right time and opportunity.
Next Steps
In the coming months, investors can anticipate the completion of the FS and possible announcements regarding project financing, with potential commencement of project development in late 2025 or early 2026. Thank you for your continued support as we navigate this exciting phase of growth.
Sincerely yours,George BeePresident and Chief Executive OfficerU.S. Gold Corp.
USAU is one of the only permitted, shovel-ready gold/copper projects in North America that is yet to be developed. Producing companies are desperate to replace dwindling ounces from their production assets. Other companies are looking to increase their production profiles to garner a re-rating from the mining analysts. US Gold is in a unique situation due to this and the M&A interest it will generate as the mining sector gains momentum.
Jurisdiction: The company’s asset is in the safest mining jurisdiction on the planet-State of Wyoming land. Wyoming is a resource/mining friendly area, with no federal nexus. This was hugely important to the permitting process of the CK Gold project and its ongoing development.
US senior exchange listing:USAU trading on the NASDAQ affords the company the ability to access retail investors throughout the US as well as institutional investors globally. With a very tight share structure, the company is very well positioned to make the most out of this burgeoning bull market.
Copper:USAU’s copper component offers diversification of the asset for those who aren’t bullish on the gold-cycle.
Other value metrics around the CK project that have not been valued into the company yet. New generation is going to be key as USAU unlocks these value markers.
Properties
CK Gold Project – Near-Term Gold – Copper Producer
The CK Gold Project deposit is a development stage, large-tonnage, gold-copper deposit with high-grade mineralization exposed at the surface surrounded by a large, low-grade zone with potential for expanding resources.
The CK Gold Project was reportedly discovered in 1881, high-graded and saw limited mining. The first exploration work reported is drilling by ASARCO in 1938. Several additional rounds of drilling have been conducted since that time. In 1972 Henrietta Mines Ltd. acquired the property and completed a comprehensive program of exploration and development. In addition to drilling, an I.P. survey, geologic mapping, geochemical sampling, and metallurgical testing were conducted (Nevin, 1973). Drilling campaigns were conducted by Saratoga since 2006 and Strathmore since 2012, with a hiatus in drill exploration until the acquisition of the project by U.S. Gold Corp. from Energy Fuels in 2014. U.S. Gold Corp. conducted drilling in 2017, 2018, 2020 and is currently concluding its 2021 drilling program, focused on data collection to support post PFS and feasibility studies in 2022.
The CK Gold Project property is located in the Silver Crown mining district of southeast Wyoming, approximately 20 miles west of the city of Cheyenne, on the southeastern margin of the Laramie Range. The property comprises about 1,120 acres (2 square miles) and is 100% owned by U.S. Gold Corp. (NASDAQ: USAU).
In December 2021, the company released the project’s SK-1300 Technical Report Preliminary Feasibility Study, PFS (by Gustavson Associates LLC). The project offers the company near-term, open-pit production potential as well as compelling value.
Highlights:
1.44 million AuEq Proven & Probable oz Reserve
Advantageous infrastructure, located near major highways and railroads, facilitates easy transportation of materials to smelters. This infrastructure advantage enhances the project’s economic viability.
100K+ oz AuEq Annual Production Forecast – plus significant upside
Mineral Resource Expansion – open at depth and laterally
All In Sustaining Cost (AISC) of $800 AuEq/ oz over LOM
Low Strip Ratio – surface mineral outcrop with immediate revenue potential
Study Underway Analyzing Aggregate Potential
Final Stages of Permitting with WY government – no federal permits needed.
CK Gold Project Pre-Feasibility Study Summary*
*Source:SK-1300 TechnicalReport Pre-FeasibilityStudy on the CK Gold Project report date December 1, 2021 using $1625 Au, $3.25 Cu and $18 Ag. Please see “CautionaryNote ConcerningMineral Resources”in this presentation
The Copper Situation
Prefeasibility Study Highlights of Ck Gold also include a staggering copper amount:
M+I includes: Gold – 1.110 million ounces and Copper – 280 million lbs!!!
Why is this a big deal?
Because copper will be a big part of the clean revolution.
Besides clean energy technologies, several industries including construction, infrastructure, and defense use copper for its unique properties. The metal is critical in many fast-growing clean industries from the electric grid and electric vehicles to renewable technologies.
Copper is essential in electrical wiring and transportation and is playing an increasingly large role in alternative energy, as it is a crucial component in wind turbines, solar panels, and electric vehicles, which require four times as much copper as conventional gas vehicles!
Some of the world’s largest mining companies and metal traders are warning that by 2025, a massive shortfall will emerge for copper, which is now the world’s most critical metal due to its essential role in the green economy.
The deficit will be so large that The Financial Post stated that it could itself hold back global growth, stoke inflation by raising manufacturing costs and throw global climate goals off course.
The copper supply issue is scary. There may not be enough copper to go around for the millions of electric vehicles (EVs) expected to hit the roads, or to fuel wind turbines and solar power.
In fact, wind and solar energy use more copper than conventional forms of energy, such as coal, natural gas, and nuclear power plants. Conventional power plants require about one ton of copper to produced one megawatt of electricity, whereas wind and solar can require between three to five tons per megawatt!
To make matters worse, these numbers only reflect the amount of copper needed to build wind turbines or solar panels, and do not factor in the additional copper needed to transport the electricity generated from wind and solar facilities to the population centers that consume the electricity.
The Next Milestones for the CK Gold Project:
Publishing an updated Prefeasibility Study (“PFS”), now slated for early 2025;
Continuing onto a final Feasibility Study (“FS”), which has already been advanced but awaits completion of the updated PFS to verify optimizations announced in September, including a final decision on the preferable flotation technology; and
Development financing opportunities with several interested parties who have been following the Company’s progress with interest.
All these activities are planned to occur during 2025 and development, subject to suitable financing, could commence as soon as year-end 2025.
U.S. Gold Corp. Announces Inaugural Digbee Assessment Results
As U.S Gold Approaches Financing Activities for the CK Gold Project, the Assessment Demonstrates that the Company is on the Right Track to Satisfy Lenders
CHEYENNE, Wyo., Feb. 26, 2025 /PRNewswire/ — U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (NASDAQ: USAU), is pleased to announce the results of an independent assessment conducted by Digbee Limited (“Digbee”). Digbee’s platform provides companies a right-sized, future-looking set of globally aligned sustainability frameworks. Digbee evaluates a comprehensive range of factors—considering both a project’s context and the effectiveness of management actions—to assign a rating from AAA to D. The overall inaugural BBB score achieved by U.S. Gold, largely for its CK Gold Project, reflects the average across all assessment criteria. We believe this rating endorses our progress and confirms that we are on track to meet and exceed the risk review criteria set by financing entities.
Operating and conducting business responsibly, by respecting local communities, protecting the environment, and maintaining strong business practices is not just about gaining acceptance and following best practices; it’s also good business sense. Companies that embed responsibility into their core operations build stronger stakeholder relationships, mitigate risks, and create long-term value. This acceptance is not only necessary for securing permits but also for obtaining the social license to operate. To date, U.S. Gold has received permits to develop its CK Gold Project in southeast Wyoming, and as we progress toward securing project financing, development lenders require assurances that all potential project risks have been addressed. These risks can span a wide spectrum, including governance (ensuring the company adheres to established business practices), environmental (complying with laws, regulations, and practices to prevent and mitigate damage to natural surroundings), and social factors (engaging local communities and securing their acceptance of project development). Development lenders, through experience, have gathered criteria to evaluate whether risks have been addressed, and their investment is secure. The Digbee platform not only helps guide companies in their activities, but it also provides investors with some comfort through an independent review that confirms risks—measured against a wide range of criteria and international best practice—have been addressed.
George Bee, President and CEO of U.S. Gold, said, “Over the last four years, we have endeavored to do things ‘the right way,’ reaching out to the local community and authorities and taking care that our disturbances resulting from exploration activities are cleared up as we go along. That same responsible attitude and the desire to be a ‘good neighbor’ as we get into development and operation is top of mind. We are pleased to share the results of this independent assessment of our activities. The assessment shows where we can still do better, but overall the BBB rating at this early stage is a great endorsement that we are on the right track as we move toward development.”
Mr. Jamie Strauss, the founder and CEO of Digbee, commented, “U.S. Gold’s completion of the Digbee assessment underscores its commitment to responsible development and transparency. By proactively evaluating risks and opportunities, the Company is positioning itself to build long-term value while meeting the evolving expectations of investors and stakeholders. This is a crucial step in demonstrating leadership and resilience in today’s mining landscape.”
The results of the Digbee assessment are available and summarized on the Company’s website and can be accessed by following the link here.
Keystone Project
Discovering the next major gold opportunity on the Cortez Trend in Nevada!
An established gold mining jurisdiction
Produced ~4.47 M oz of gold produced in 2021 – approx. 78% of U.S. gold production *USFunds.com
6th largest gold producing “country” in the world, if Nevada were a country
Historically, Nevada has produced > 225M oz of gold, hosting numerous world-class deposits
“Elephant country”: >20M oz gold deposits
Pro-mining environment, geopolitical stability, major infrastructure Keystone Project Location Keystone exhibits many similarities to Barrick’s deposits to the north; similar host rock, stratigraphy, structure and Eocene intrusions
Priority Target Areas:
Consolidated an entire district on the Cortez Trend, NV – 20 square miles, 100% controlled by U.S. Gold Corp.
Never previously consolidated nor systematically explored by model -driven, modern -day exploration techniques
The extent and intensity of the alteration and the thickness of permissive rock packages encountered, highlight the potential of this district-scale mineral system
Systematic exploration has primed Keystone for discovery
Recent hyperspectral survey undergoing ground investigation for potential additional targets
Mr. Bee is a senior mining industry executive, with deep mine development and operational experience. He has an extensive career advancing world-class gold mining projects in eight countries on three continents for both major and junior mining companies. Most recently in 2018 Mr. Bee concluded a third term with Barrick Gold as Senior VP Frontera District in Chile and Argentina to advance Pascua Lama feasibility as an underground mine. This capped a 16-year history with Barrick Gold with positions that included Mine Manager at Goldstrike during early development and operations, Operations Manager at Pierina Mine taking Pierina from construction to operations, and General Manager of Veladero developing the project from advanced exploration through permitting, feasibility and into production.
With his Barrick experience and having had eight years in South Africa working underground gold with Anglo American and open pit copper with Rio Tinto at Palabora Mine, Mr. Bee was well placed to advance projects internationally and domestically as a senior executive. This led to his appointment to various board and leadership positions at various companies. As COO of Aurelian Resources in 2007, he was in charge of project development for Fruta del Norte in Ecuador until Aurelian was acquired by Kinross Gold in 2008. Post-acquisition, moving on from Kinross, where he had also previously worked from 1996 to 1998 advancing projects in El Salvador and Nevada, he joined Andina Minerals as CEO in 2009. Andina and its 6 million-ounce Volcan Gold Project in Chile was acquired by Hochschild in 2013. By this time Mr. Bee had been appointed to the boards of Peregrine Metals and later Stillwater Mining and Jaguar Mining. In 2014, he also assumed the role of Chief Executive Officer of Jaguar Mining, operating mines in Brazil, as the company emerged from a financial restructuring process.
Mr. Bee is a graduate of the Camborne School of Mines in Cornwall, United Kingdom and is a member of the Institute of Corporate Directors with an ICD.D designation.
Eric Alexander
CHIEF FINANCIAL OFFICER AND CORPORATE SECRETARY
Mr. Eric Alexander has over 30 years of corporate, operational and business experience, and over 15 years of mining industry experience. Previously he served as Corporate Controller of Helix Technologies, Inc., a publicly traded software and technology company from April 2019 to September 2020. Prior to that, he served as the Vice President Finance and Controller of Pershing Gold Corporation, a mining company (formerly NASDAQ: PGLC), from September 2012 until April 2019. Prior to that, Mr. Alexander was the Corporate Controller for Sunshine Silver Mines Corporation, a privately held mining company with exploration and pre-development properties in Idaho and Mexico, from March 2011 to August 2012. He was a consultant to Hein & Associates LLP from August 2012 to September 2012 and a Manager with Hein & Associates LLP from July 2010 to March 2011. He served from July 2007 to May 2010 as the Corporate Controller for Golden Minerals Company (and its predecessor, Apex Silver Mines Limited), a publicly traded mining company with operations and exploration activities in South America and Mexico. In addition to his direct experience in the mining industry, he has also held the position of Senior Manager with the public accounting firm KPMG LLP, focusing on mining and energy clients. Mr. Alexander has a B.S. in Business Administration (concentrations in Accounting and Finance) from the State University of New York at Buffalo and is also a licensed CPA.
Kevin Francis
VICE PRESIDENT – EXPLORATION & TECHNICAL SERVICES
Mr. Francis has held many senior roles within the mining industry, including VP of Project Development for Aurcana Corporation, VP of Technical Services for Oracle Mining Corporation, VP of Resources for NovaGold Resources and Principal Geologist for AMEC Mining and Metals. Most recently, he consulted to U.S. Gold Corp. as Principal of Mineral Resource Management LLC, a consultancy providing technical leadership to the mining industry, as well as the CK Gold Project through his association with Gustavson Associates (a member of WSP) since September 2020. Mr. Francis is a member of the Board of Directors of Texas Mineral Resources Corporation. Mr. Francis is a “Qualified Person” as defined by SEC S-K 1300 and Canadian NI 43-101 reporting standards and holds both an M.S. degree and a B.A. in geology from the University of Colorado.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY USAU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
The Company Has Recently Announced Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
We had a busy week and are coming off of a high flying 20%+ mover that we profiled on Thursday. We expect that this week could be equally as busy. We are going to do something that we have not done in many years here.
We are going to take a look at a company that you aren’t going to find on Robinhood or Webull. I know what you are going to say…… How does a company with over $300M in expected revenue this past year not trade on Robinhood?
The simple answer is that is all in the works right now.
BSEM realizes that it is a 9 figure revenue producer and it is limiting it’s audience be continuing to trade on the OTC.
All of the necessary forms have been filed and now it is a waiting game.
Make no mistake, once BSEM is trading on the nasdaq, an accomplishment that many set out to do but few accomplish, then this one is going to get a tremendous amount of new eyes on it that were previously unaware of BSEM and their massive accomplishments.
Take a look at the one year and three month charts below.
BSEM is definitely a mover with some lofty $30+ price targets on it.
NOTEABLE BSEM CATALYSTS:
Working with notable clients and partners including the Center of Medicare Services (CMS), and the U.S. Department of Veterans Affairs (VA).
Specially trained salespeople recently installed could be very effective in explaining the benefits available from using the company’s product. BSEM has added industry veterans Mirlene Guerre as Vice President of Sales and Neal Bhattcharya as Vice President of Marketing. Ms. Guerre has extensive experience leading sales teams and organizations in wound care, burn, plastics, general, and oral/ent surgical markets. Mr. Bhattacharya has held progressive positions in marketing for well-known national brands in both consumer packaged goods and medical device companies, including Kimberly-Clark, Novartis, Covidien and Trividia Health, Inc.
The company has entered into an Agreement to acquire the majority of the assets of Auxocell Laboratories, Inc., a leading solid tissue processing equipment manufacturer. The acquisition will enable BSEM to expand its intellectual property portfolio, both domestic and foreign, in the perinatal tissue space and provide additional value to clients and shareholders.
To date, the company has produced over 20,000 allografts, including its own Vendaje® line of products as well as contract manufacturing for many key industry players.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). The company’s facility is also FDA-accredited.
Biostem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
The company is providing a vital service to the human population while working to provide economic value to shareholders as well.
BSEM manufactures perinatal tissue allografts and is focused on the diabetic wound care market and the surgical wound care market.
BioStem CEO Jason Matuszewski and Chief Operating Officer Andrew Van Vurst co-founded the company in 2014. When Van Vurst’s father developed side effects from radiation treatment for cancer, resulting in partial paralysis and speech impairment, Van Vurst returned from the military to explore treatment options that would help his father regain motor function, speech and overall quality of life.
These included regenerative medicine, utilizing material derived from a human umbilical cord, that was being used to help restore tissues or organ damage because of age, disease, injury or other issues.
In 2013, Van Vurst and his father discovered South Florida-based Caribbean International Holdings, a provider of stem cell treatments.
The regenerative medicine therapy proved to be a great success for Van Vurst’s father, who regained his speech, and vastly improved his motor skills and overall quality of life. Due to the success of the treatment, Van Vurst and his father developed a passion for regenerative medicine and BioStem was born.
Future Medicine: Regenerative Therapies
It’s no secret that the human body has an amazing ability to heal itself. You may have heard the term regenerative medicine before. It’s basically where the body uses its own systems to rebuild tissues and organs.
With its potential to heal, regenerative medicine has become a VERY hot topic and is expected to revolutionize healthcare.
The market for regenerative medicine is expected to experience significant growth over the next few years. It comes as no surprise that some of the biggest companies in healthcare are working hard to make advances in this vital space. This includes major players like Amgen, Sanofi, and Gilead Sciences.
A report from Grand View Research projects that the global stem cell market will reach a massive US$18.4 billion by 2028.
The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market.
Grand View Research has also highlighted that many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration.
Harnessing Placental Tissue for Regenerative Therapies
BSEM manufactures tissue allografts that come from the human placenta. This is essentially a tissue transplant product from the placenta. In the space of skin substitutes, it is like xenografts or grafts from an animal.
What is an allograft?
An allograft is a tissue that is transplanted from one person to another. The prefix allo comes from a Greek word meaning “other.” (If tissue is moved from one place to another in your own body, it is called an autograft.) More than 1 million allografts are transplanted each year.
The Company’s Allografts Are Not Just Any Allografts…. They Are Best-In-Class Placental Tissue Allografts!
The proprietary BioRetain® processing method.
BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure.
The company’s portfolio of quality brands includes VENDAJE™, VENDAJE™ AC,VENDAJE™ OPTIC and AMNIOWRAP2.
Each BioStem Technologies placental allograft is processed at the Company’s FDA-registered and AATB-accredited site in Pompano Beach, Florida.
Already Working with Notable Clients and Partners, BSEM is Paving the Way in Modern Medicine with Substantial Growth Potential!
BSEM is focused on the application of tissue engineering in wound healing and has curated a suite of versatile products called Vendaje.
Vendaje is the company’s primary product and harnesses elements of perinatal tissue and the body’s innate biology to repair and restore damaged tissue in wounds, resulting in speedier healing with reduced pain.
Vendaje comes in several different forms and sizes and is a human connective tissue matrix comprised of amniotic tissue. This amniotic tissue is processed using the company’s proprietary BioRetain process, which creates a dehydrated human amniotic membrane allograft.
Placentally-derived human amniotic membrane (AM) is a source of pro-healing growth factors and anti-inflammatory cytokines and has successfully been used in regenerative medicine for over a century.
Vendaje is the result of the modernization of this science.
VENDAJE™ is offered to all Medicare providers across the United States. On January 1, CMS established and published the national pricing data for reimbursement based on the Average Sales Price (“ASP”) of VENDAJE™. Establishing national pricing for VENDAJE™ enables BioStem to offer its product to all Medicare providers across the U.S.
VENDAJE™, VENDAJE ACTM, VENDAJE OPTICTM, and AMNIOWRAP2TM are the only allografts available that leverage the company’s proprietary BioREtain processing technology.
BSEM has entered an agreement with leading US wound market solutions provider, Venture Medical, LLC., for the nationwide release of its innovative product, AmnioWrap2™.
A leading wound market solutions provider called Venture Medical, LLC., will lead the company’s commercialization of AmnioWrap2™!
AmnioWrap2 is a versatile allograft solution for wound applications. It is an advanced biologic skin substitute that is meticulously processed to offer an extensive range of wound healing and wound care solutions.
“AmnioWrap2™, is the latest addition to BioStem’s product portfolio, and is developed using its proprietary BioREtain process.
This process creates an allograft derived from amniotic tissue, optimized to cater to diverse wound care applications.”
The launch of AmnioWrap2 signifies a pivotal milestone as the company expands its spectrum of innovative solutions within the wound care market.
According to the company, early users of AM for wounds and post-surgical applications noted how the membrane seemed to disappear and integrate with the patient’s own tissue without a host reaction. This apparent immune neutrality is a result of mechanisms that suppress and modulate the immune system.
The increased adoption of perinatal tissues has allowed for its significant penetration into the multibillion-dollar soft tissue repair market, which is expected to reach around $8.6B by 2030!
As more doctors become familiar with the BSEM technology, it could open doors to many revenue opportunities!
Two Big Markets
Perinatal tissue allografts have been successfully used since the early 1900’s as an alternative modality for the treatment for chronic wounds.
More recently physicians have used these products to treat ocular surface disorders, chronic non-healing diabetic wounds, and in a variety of surgical procedures.
The market for products BSEM has developed and is continuing to develop is extensive and this cutting-edge technology can prove to be a game-changer to many patients suffering from painful and slow recoveries.
Both the diabetes wound care market and surgical recovery wound care market are growing at a tremendous rate.
Because diabetes and issues from diabetes are increasing worldwide, this offers an opportunity for BSEM’s allografts to help patients.
The global wound care market in terms of revenue was estimated to be worth $20.8 billion in 2022 and is poised to reach $27.2 billion by 2027, growing at a CAGR of 5.4% from 2022 to 2027.
The US advanced wound care market in terms of revenue was estimated to be worth 11.2 billion in 2022 and is poised to reach 17.7 billion in 2027 at a compound growth rate (CAGR) of 9.4% from 2022-2027.
The global diabetic foot ulcer treatment market size was valued at $4.67 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030.
There is promising potential for BSEM to impact patients and expand the company’s business in an exponential way as more doctors become familiar with the company’s technology!
BREAK THROUGH RESULTS!
Breakthrough results published in the peer-reviewed journal, International Wound Journal. The study validates the clinical efficacy ofBioREtain®-processed placental membranes (RE-AC) compared to the standard of care (SOC). Utilizing a real-world population with large, hard-to-heal, complex chronic diabetic foot ulcers (DFUs), the study demonstrates a clear advantage in 12-week wound healing rates for the RE-AC-treated group compared to the SOC group.
BSEM released study results that showed the company’s signature technology, BioREtain, showed superior performance over the traditional standard of care.
According to the company, in this study, researchers conducted a retrospective analysis to evaluate the effectiveness of a sterile, dehydrated amnion/chorion membrane processed using a proprietary method (BioREtain-AC) compared to a cohort of patients treated with standard of care measures in healing hard-to-heal diabetic foot ulcers in a real-world environment. A total of 21 subjects met the study’s inclusion criteria, which included factors such as wound type, medical history, and previous treatment involving the BioREtain-AC placental membrane product. The wounds in the study were considerably larger than those typically included in randomized controlled trials, averaging nearly 14 cm², compared to an average wound size of about 5 cm² in most trials.
The study demonstrated that patients treated with BioREtain experienced an 8.53% higher probability of achieving full wound closure compared to the standard of care group after 12 weeks. For those wounds that did not achieve complete closure, the BioREtain group still showed a 93.6% improvement in expected area reduction, while the standard of care group stalled or grew larger.
This confirms that BSEM technology is superior and very helpful to patients. More doctors are turning to BioStem for treatments, resulting in increasing sales.
Also likely helping to boost sales was the company’s announcement that the Center for Medicare Services has established a national pricing for the company’s product Vendaje AC!
CEO Jason Matuszewski notes that, “With CMS’s national pricing approval, Vendaje AC is now accessible to more patients across the country.”
Receiving a Q Code
Being was awarded a Q code that became effective on January 1, 2024!
It applies to drugs, biologics, and medical equipment and services that are not identified by the national code needed for Medicare claims processing. It allows these “Q” products to be reimbursed by Medicare.
Zacks Smallcap Research previously noted: “With the company’s recent announcement of a Q code, we believe rapid growth is set to continue and are raising our valuation level as a result.”
With BSEM’s revenues skyrocketing, the company securing a CMS Q code, game-changing partnerships, a successful capital raise, and the start of a crucial clinical trial for diabetic foot ulcers… BSEM is a stock to watch.
BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting
April 30, 2025
BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025
April 21, 2025
BioStem Technologies to Present at the Centri Capital Conference
April 14, 2025
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
April 8, 2025
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
April 1, 2025
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
March 31, 2025
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
March 27, 2025
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
February 24, 2025
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
January 13, 2025
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
MANAGEMENT TEAM
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY BSEM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.